

ID V61168 standard; cDNA; 234 BP.

```
AC V61168;
DT 06-JAN-1999 (first entry)
DE cDNA sequence of prostate tumour clone P20.
KW Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN WO9837093-A2.
PD 27-AUG-1998.
PE 25-FEB-1998; US-020956.
PR 09-FEB-1998; US-020956.
PR 25-FEB-1997; US-806099.
PR 01-AUG-1997; US-904804.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI: 98-609886/51.
PT Polypeptides comprising immunogenic portions of prostate proteins -
PS used in a vaccine for the treatment of prostate cancer
PS Claim 3; Page 53-54; 130pp; English.
CC The present sequence is a new DNA which encodes an immunogenic portion
CC of a prostate tumour protein. The encoded immunogen, or the DNA itself,
CC can be used as a vaccine for the treatment of prostate cancer. The DNA
CC was identified by analysis of a subtracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
CC tissue cDNA library.
SQ Sequence 234 BP; 43 A; 68 C; 68 G; 55 T;

Query Match 100.0%; Score 234; DB 1; Length 234;
Best Local Similarity 100.0%; Pred. No. 2.4e-61;
Matches 234; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 acaacagacccttgctgcgtacagaccctatgctcatcaagtgtgagcgaatccgtgtccg 60
DB 1 ACAACAGACCCCTTGCTGCTGCTAAGACCTCATGCTCATCAAGTTGACGAGATCCGTGTCCG 60

QY 61 agctgcacacatccggagacatcagcattgtctgcagtgccctaccgsgggaaactctt 120
DB 61 AGCTGACACACATCCGGAGACATCAGCATTCCTTCGACAGTCCCTACCGGGGAACTCTT 120

QY 121 gccctgtcttcgtcggtgtctgtcgtgagagcgagaaatgcttaccgtgctgagtggtg 180
DB 121 GCCTGCTTCTGCTGCGGTGCTGCTGCTGCGAAGCGGCAATGCCCTACCGTGTGCAAGTGGC 180

QY 181 tgaacgtgtcggtgtgtgtctgtgagagaggtctgcagtaagctctatgacccgctgt 234
DB 181 TGAAGTGTGCGGTGTGTGTGTGTGAGAGAGTGTGCAAGTGTATGACCCGCTGT 234

RESULT 3
AC V58644 standard; cDNA; 1248 BP.
DE 08-DEC-1998 (first entry)
DE Prostate tumour specific gene clone DEL.
KW Prostate tumour specific gene; human; prostate cancer; detection;
OS Homo sapiens.
FH Key Location/Qualifiers
FT CDS 217..696
FT /*tag= a
PN WO9837418-A2.
PD 27-AUG-1998.
PE 25-FEB-1998; US-03690.
PR 09-FEB-1998; US-904809.
PR 25-FEB-1997; US-806596.
PR 01-AUG-1997; US-904809.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI: 98-480805/41.
DR P-PSDB: W69387.
PT Novel human prostate specific tumour protein and fragments - useful
PT for detecting and treating prostate cancers
PS Claim 1; Page 112; 141pp; English.
CC This sequence represents a human prostate tumour specific gene, and can
```

```
CC be used in the method of the invention. The method is for detecting
CC prostate cancer comprising contacting a biological sample with an agent
CC able to bind an immunogenic portion of a prostate protein (such as
CC encoded by this sequence). An antibody which binds to an immunogenic
CC portion of the prostate protein, and the method can be used to detect,
CC monitor progression of, or treat prostate cancers. The antibody may
CC also be conjugated to a therapeutic agent for use in therapy of prostate
CC cancers.
SQ Sequence 1248 BP; 288 A; 424 C; 303 G; 228 T;

Query Match 100.0%; Score 234; DB 1; Length 1248;
Best Local Similarity 100.0%; Pred. No. 3.8e-61;
Matches 234; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 acaacagacccttgctgcgtacagaccctatgctcatcaagtgtgagcgaatccgtgtccg 60
DB 254 ACAACAGACCCCTTGCTGCTGCTAAGACCTCATGCTCATCAAGTTGACGAGATCCGTGTCCG 313

QY 61 agctgcacacatccggagacatcagcattgtctgcagtgccctaccgsgggaaactctt 120
DB 314 AGCTGACACACATCCGGAGACATCAGCATTCCTTCGACAGTCCCTACCGGGGAACTCTT 373

QY 121 gccctgtcttcgtcggtgtctgtcgtgagagcgagaaatgcttaccgtgctgagtggtg 180
DB 374 GCCTGCTTCTGCTGCGGTGCTGCTGCTGCGAAGCGGCAATGCCCTACCGTGTGCAAGTGGC 433

QY 181 tgaacgtgtcggtgtgtgtctgtgagaggtctgcagtaagctctatgacccgctgt 234
DB 434 TGAAGTGTGCGGTGTGTGTGTGTGAGAGAGTGTGCAAGTGTATGACCCGCTGT 487

RESULT 4
AC V61249 standard; cDNA; 1248 BP.
DE 06-JAN-1999 (first entry)
DE cDNA sequence of prostate tumour clone P703 splice variant DEL.
KW Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN WO9837093-A2.
PD 27-AUG-1998.
PE 25-FEB-1998; US-03492.
PR 09-FEB-1998; US-020956.
PR 25-FEB-1997; US-806099.
PR 01-AUG-1997; US-904804.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI: 98-609886/51.
DR P-PSDB: W71871.
PT Polypeptides comprising immunogenic portions of prostate proteins -
PT used in a vaccine for the treatment of prostate cancer
PS Claim 3; Page 104; 130pp; English.
CC The present sequence is a new DNA which encodes an immunogenic portion
CC of a prostate tumour protein. The encoded immunogen, or the DNA itself,
CC can be used as a vaccine for the treatment of prostate cancer. The DNA
CC was identified by analysis of a subtracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
CC tissue cDNA library.
SQ Sequence 1248 BP; 288 A; 424 C; 303 G; 228 T;

Query Match 100.0%; Score 234; DB 1; Length 1248;
Best Local Similarity 100.0%; Pred. No. 3.8e-61;
Matches 234; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 acaacagacccttgctgcgtacagaccctatgctcatcaagtgtgagcgaatccgtgtccg 60
DB 254 ACAACAGACCCCTTGCTGCTGCTAAGACCTCATGCTCATCAAGTTGACGAGATCCGTGTCCG 313

QY 61 agctgcacacatccggagacatcagcattgtctgcagtgccctaccgsgggaaactctt 120
DB 314 AGCTGACACACATCCGGAGACATCAGCATTCCTTCGACAGTCCCTACCGGGGAACTCTT 373
```

Query Match	100.0%	Score 234:	DB 1:	Length 1386:
Best Local Similarity	100.0%	Pred. No. 3.9e-61:		
Matches 234:	Conservative	0:	Mismatches 0:	Indels 0: Gaps 0:
Db	1	acaacagaccccttgctgcgtacagacccatgctcatcaagttggaagcaatccgctgctcg	60	
Db	234	ACAAACAGACCCCTTGCTGCCTACGACCCATCATGCTTCGACGTGCCCTACCGGGGAACTCTT	293	
Db	61	agtcgaaacccatccggagagcatcaagattgctgcagtgccctaacgcggggaactctt	120	
Db	294	ACTCTGACACCAATCCGGACATCAGCATTTGCTTCGACGTGCCCTACCGGGGAACTCTT	353	
Db	121	gcctgcttcttgctgcgggctgcctgcggcgaaagcgaggaatgctcaccggtgcgaattg	180	
Db	354	GCCTGCTTCTTGCTGCGGGCTCTGCTGCGCAAGCGCAGATGCCCTACCGGTCTGCACTGCG	413	
Db	181	tgaacgtctcggtggtgtcttggaaggtctgcagtaagctctatgacccgctgt	234	
Db	434	TGAACGTCTCGGTGCTGTCTGAGGAGGTGTGCAATGAGCTATGACCCGCTGT	487	
RESULT	5			
ID	V11855	standard; cDNA: 1386 BP.		
AC	V11855:			
DE	11-SEP-1998 (first entry)			
DE	Home sapiens Tub Interactor (htr-1) gene.			
DE	serine protease; tub interactor; treatment; obesity; cachexia;			
DE	anorexia nervosa; diabetes; cell cycle progression; apoptosis;			
DE	neurodegenerative disease; Alzheimer's disease; drug screening;			
DE	Parkinson's disease; Huntington's chorea; detection; diagnosis;			
DE	amyotrophic lateral sclerosis; spinocerebellar degeneration; ss.			
DE	Hom sapiens.			
DE	Key	Location/Qualifiers		
DE	CDS	2..701		
DE	FT	/*tag="		
DE	FT	/product="htr-1 protein		
DE	FT	/note="putative serine protease"		
DE	PN	MO9812302-A1.		
DE	PD	26-MAR-1998.		
DE	PF	05-SEP-1997: U15627.		
DE	PR	21-JUL-1997: US-897340.		
DE	PR	17-SEP-1996: US-715032.		
DE	PA	(MILL-) MILENNIUM PHARM INC.		
DE	PI	Errata PR, Gilmemo CJ;		
DE	DR	WPI: 98-217246/19.		
DE	P-PSDB:	W59129.		
DE	PT	Tub interactor genes - used to develop products for the treatment		
DE	PT	of obesity, cachexia, anorexia nervosa or related disorders e.g.		
DE	PT	diabetes		
DE	PS	Claim 10: Fig 1, 120pp; English.		
DE	CC	The sequence is that of the tub interactor gene htr-1 which		
DE	CC	codes for a putative serine protease. T1 genes function		
DE	CC	in biochemical pathways involved in weight control and		
DE	CC	related disorders. The products can be used for treating		
DE	CC	weight disorders, e.g. obesity, cachexia or anorexia nervosa,		
DE	CC	or a related disorder such as diabetes. The products can		
DE	CC	also be used to modulate cell cycle progression and apoptosis.		
DE	CC	They can be used for treating neurodegenerative diseases		
DE	CC	which are characterised by apoptosis, including Alzheimer's		
DE	CC	disease, Parkinson's disease, Huntington's chorea, amyotrophic		
DE	CC	lateral sclerosis or spinocerebellar degenerations. The		
DE	CC	products can also be used for detection, diagnosis and		
DE	CC	drug screening.		
DE	SO	Sequence 1386 BP; 318 A; 490 C; 321 G; 249 T;		

RESULT	6	
ID	V58647	standard; cDNA; 1167 BP.
AC	V58647:	
DT	08-DEC-1998	(first entry)
DE	Prostate tumour specific gene clone DE13.	
KW	Prostate tumour specific gene; human; prostate cancer; detection;	
KW	therapy; ss.	
OS	Homo sapiens.	
PH	Key	Location/Qualifiers
FT	CDS	28..645
FT	/*tag= a	
PN	W09837418-A2.	
PD	27-AUG-1998.	
PF	25-FEB-1998:	U03690.
PR	09-FEB-1998:	US-804809.
PR	25-FEB-1997:	US-806596.
PR	01-AUG-1997:	US-904809.
PA	(CORI-) CORIXA CORP.	
PI	Dillon DC, Xu J;	
DR	WPI: 98-480805/41.	
DR	P-PSDB: W69388.	
PT	Novel human prostate specific tumour protein and fragments - useful	
PT	for detecting and treating prostate cancers	
PT	Claim 1; Page 115; 141pp: English.	
CC	This sequence represents a human prostate tumour specific gene, and can	
CC	be used in the method of the invention. The method is for detecting	
CC	prostate cancer comprises contacting a biological sample with an agent	
CC	able to bind an immunogenic portion of a prostate protein (such as	
CC	encoded by this sequence). An antibody which binds to an immunogenic	
CC	portion of the prostate protein, and the method can be used to detect,	
CC	monitor progression of, or treat prostate cancers. The antibody may	
CC	also be conjugated to a therapeutic agent for use in therapy of prostate	
CC	cancers.	
CC	Sequence 1167 BP; 242 A; 400 C; 287 G; 222 T;	
Query Match	97.8%; Score 228.8; DB 1; Length 1167;	
Best Local Similarity	98.3%; Pred. No. 1.3e-59;	
Matches 230; Conservative	0; Mismatches 4; Indels 0; Gaps 0;	
Db	1	acaagaagacccttgctgcctacagaccctcagctcctacaaattgtagaactccgtgtcgcg 60
Db	203	ACAAAGAGACTCTTGTCTCGCTACGACCTCATGCTCATCAAGTGGACGAATCCGTGTCG 262
Qy	61	agcttgaaccacccgcgagacatcaagattgtcttcgcagtcgcctaccgcg99gaactcct 120
Db	263	AGCTGACACCATCCGCGAGCATCAGCATTCGTCGCAATGCCCTACGCCGGGGAACCTT 322
Qy	121	gctctggttctcgtcgtcgtggtctgtctgtcgtcgaacgcagaaagtgcctaccgtgtcgcag 180
Db	323	GCCCTGCTTCGTGGCTGGGGGCTGTGCTGGCGGAACGCCGAATACCTCCGTGCGACTGCG 382
Qy	181	tgaagttcgtggtgtgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgt 234
Db	383	TGAACGTGTCGCTGTGTCTGTAGGANGTCTGCAGTAACTCATGACCCCGCTGT 436
RESULT	7	
ID	V61252	
AC	V61252	standard; cDNA; 1167 BP.
DT	06-JAN-1999	(first entry)
DE	cDNA sequence of prostate tumour clone P703 splice variant DE13.	
KW	Prostate; cancer; tumour; vaccine; immunogen; clone; ss.	
OS	Homo sapiens.	
PN	W09837093-A2.	
PD	27-AUG-1998.	
PF	25-FEB-1998:	U034992.

Query Match

66.2%; Score 155; DB 1; Length 402;

Best Local Similarity 100.0%; Pred. No. 1.2e-37;
Matches 155; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 acaacagacccttgctgcgaacacatcatgctcatcaagtggagcaatcgtgcg 60
DB 242 ACAACAGACCCCTTGCTGCTAAGACACCTCATGCTCATCAAGTTGGAGAAATCCGTGCG 301
QY 61 agctgcaccatccggaagcatcagcatcttcgcagtgccctaccgcggaactctt 120
DB 302 AGCTGACACCATCCGAGCATCGCATTTGCTGCAAGTGCCTACCGCGGGGAACCTCT 361
QY 121 gctcgtttcgtggtggtctgctgcaagcg 155
DB 362 GCCCTGTTTCTGCTGGGGTCTGCTGGCAACGCG 396

BLT 10
V58645

ID V58645 standard; cDNA; 1265 BP.

AC V58645;

DT 08-DEC-1998 (first entry)

DE Prostate tumour specific gene clone DE2.

KW Prostate tumour specific gene; human; prostate cancer; detection;

KM therapy; ss.

OS Homo sapiens.

PN W09837418-A2.

PD 27-AUG-1998.

PF 25-FEB-1998; US-904809.

PR 09-FEB-1998; US-904809.

PR 25-FEB-1997; US-806596.

PR 01-AUG-1997; US-904809.

PA (COR-) CORIXA CORP.

PI Dillion DC, Xu J;

DR WPI; 98-480805/41.

PT Novel human prostate specific tumour protein and fragments - useful

PS Claim 1: Page 113-114; 141pp; English.

CC This sequence represents a human prostate tumour specific gene, and can
CC be used in the method of the invention. The method is for detecting
CC prostate cancer comprises contacting a biological sample with an agent
CC able to bind an immunogenic portion of a prostate protein (such as
CC encoded by this sequence). An antibody which binds to an immunogenic
CC portion of the prostate protein, and the method can be used to detect,
CC monitor progression of, or treat prostate cancers. The antibody may
CC also be conjugated to a therapeutic agent for use in therapy of prostate
CC cancers.

SQ Sequence 1265 BP; 256 A; 432 C; 321 G; 245 T;

Query Match

65.8%; Score 154; DB 1; Length 1265;

Best Local Similarity 100.0%; Pred. No. 3.1e-37;
Matches 154; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 acaacagacccttgctgcgaacacatcatgctcatcaagtggagcaatcgtgcg 60
DB 215 ACAACAGACCCCTTGCTGCTAAGACACCTCATGCTCATCAAGTTGGAGAAATCCGTGCG 274
QY 61 agctgcaccatccggaagcatcagcatcttcgcagtgccctaccgcggaactctt 120
DB 275 AGCTGACACCATCCGAGCATCGCATTTGCTGCAAGTGCCTACCGCGGGGAACCTCT 334
QY 121 gctcgtttcgtggtggtctgctgcaagcg 154
DB 335 GCCCTGTTTCTGCTGGGGTCTGCTGGCAACGCG 368

RESULT 11

V61250

ID V61250 standard; cDNA; 1265 BP.

AC V61250;

DT 06-JAN-1999 (first entry)

DE cDNA sequence of prostate tumour clone P703 splice variant DE2.

KW Prostate; cancer; tumour; vaccine; immunogen; clone; ss.

OS Homo sapiens.

PN W09837093-A2.

PD 27-AUG-1998.

PF 25-FEB-1998; US-904809.

PR 09-FEB-1998; US-904809.

PR 25-FEB-1997; US-806099.

PR 01-AUG-1997; US-904809.

PA (COR-) CORIXA CORP.

PI Dillion DC, Xu J;

DR WPI; 98-609886/51.

PT Polypeptides comprising immunogenic portions of prostate proteins -

PS used in a vaccine for the treatment of prostate cancer

PS Claim 3: Page 105-106; 130pp; English.

CC The present sequence is a new DNA which encodes an immunogenic portion

CC of a prostate tumour protein. The encoded immunogen, or the DNA itself,

CC can be used as a vaccine for the treatment of prostate cancer. The DNA

CC was identified by analysis of a subtracted cDNA library obtained by

CC subtracting a prostate tumour cDNA expression library with a normal

CC tissue cDNA library.

SQ Sequence 1265 BP; 256 A; 432 C; 321 G; 245 T;

Query Match

65.8%; Score 154; DB 1; Length 1265;

Best Local Similarity 100.0%; Pred. No. 3.1e-37;
Matches 154; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 acaacagacccttgctgcgaacacatcatgctcatcaagtggagcaatcgtgcg 60
DB 215 ACAACAGACCCCTTGCTGCTAAGACACCTCATGCTCATCAAGTTGGAGAAATCCGTGCG 274
QY 61 agctgcaccatccggaagcatcagcatcttcgcagtgccctaccgcggaactctt 120
DB 275 AGCTGACACCATCCGAGCATCGCATTTGCTGCAAGTGCCTACCGCGGGGAACCTCT 334
QY 121 gctcgtttcgtggtggtctgctgcaagcg 154
DB 335 GCCCTGTTTCTGCTGGGGTCTGCTGGCAACGCG 368

RESULT 12

V58646

ID V58646 standard; cDNA; 1459 BP.

AC V58646;

DT 08-DEC-1998 (first entry)

DE Prostate tumour specific gene clone DE6.

KW Prostate tumour specific gene; human; prostate cancer; detection;

KM therapy; ss.

OS Homo sapiens.

PN W09837418-A2.

PD 27-AUG-1998.

PF 25-FEB-1998; US-904809.

PR 09-FEB-1998; US-904809.

PR 25-FEB-1997; US-806596.

PR 01-AUG-1997; US-904809.

PA (COR-) CORIXA CORP.

PI Dillion DC, Xu J;

DR WPI; 98-480805/41.

PT Novel human prostate specific tumour protein and fragments - useful

PS Claim 1: Page 114; 141pp; English.

CC This sequence represents a human prostate tumour specific gene, and can

CC be used in the method of the invention. The method is for detecting

CC prostate cancer comprises contacting a biological sample with an agent

CC able to bind an immunogenic portion of a prostate protein (such as

CC encoded by this sequence). An antibody which binds to an immunogenic

CC portion of the prostate protein, and the method can be used to detect,

CC monitor progression of, or treat prostate cancers. The antibody may

CC also be conjugated to a therapeutic agent for use in therapy of prostate

CC cancers.

SQ Sequence 1459 BP; 427 A; 328 C; 406 G; 295 T;

Query Match 65.8%; Score 154; DB 1; Length 1459;
Best Local Similarity 100.0%; Pred. No. 3.2e-37;
Matches 154; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 acacagacccctgtctgcttaacgacctatcatcaagtggagcaatccgtgtccg 60
DB 136 ACAACAGACCCCTGTGCTGCTTAACGACCTCATGCTCATCAAGTTGACGAAATCCGTGTCG 195
QY 61 agcttgacacatcccgagacatcagcatgtctgcagtgccctacgcgagggaacctctt 120
DB 196 AGCTGACACCATCCGAGACATCAGCATTTGCTTCGACGTGCCCTACCGCGGGAACCTCTT 255
QY 121 gccctgttctggctgggtgtctgctggcgaaacgg 154
DB 256 GCCTCGTTTCTGGCTGGGGGTCTGCTGGCGAACGG 289

RESULT 13
V61251 standard; cDNA; 1459 BP.
AC V61251;
DT 06-JAN-1999 (first entry)
DE cDNA sequence of prostate tumour clone P703 splice variant DE6.
KW Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN MO9837093-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; US-020956.
PR 09-FEB-1998; US-020956.
PR 25-FEB-1997; US-806099.
PR 01-AUG-1997; US-904804.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI: 98-609886/51.
PT Polypeptides comprising immunogenic portions of prostate proteins -
PS used in a vaccine for the treatment of prostate cancer
PS Claim 3; Page 106; 130pp; English.
CC The present sequence is a new DNA which encodes an immunogenic portion
CC of a prostate tumour protein. The encoded immunogen, or the DNA itself,
CC can be used as a vaccine for the treatment of prostate cancer. The DNA
CC was identified by analysis of a substracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
CC tissue cDNA library.
SO Sequence 1459 BP; 427 A; 328 C; 406 G; 295 T;

Query Match 65.8%; Score 154; DB 1; Length 1459;
Best Local Similarity 100.0%; Pred. No. 3.2e-37;
Matches 154; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 acacagacccctgtctgcttaacgacctatcatcaagtggagcaatccgtgtccg 60
DB 136 ACAACAGACCCCTGTGCTGCTTAACGACCTCATGCTCATCAAGTTGACGAAATCCGTGTCG 195
QY 61 agcttgacacatcccgagacatcagcatgtctgcagtgccctacgcgagggaacctctt 120
DB 196 AGCTGACACCATCCGAGACATCAGCATTTGCTTCGACGTGCCCTACCGCGGGAACCTCTT 255
QY 121 gccctgttctggctgggtgtctgctggcgaaacgg 154
DB 256 GCCTCGTTTCTGGCTGGGGGTCTGCTGGCGAACGG 289

RESULT 14
V58648 standard; cDNA; 1119 BP.
AC V58648;
DT 08-DEC-1998 (first entry)
DE Prostate tumour specific gene clone DE14.
KW Prostate tumour specific gene; human; prostate cancer; detection;
therapy; ss.

OS Homo sapiens.
FH Key Location/Qualifiers
FT CDS 34..528
FT CDS /*tag= a
FN MO9837418-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; US-03690.
PR 09-FEB-1998; US-904809.
PR 25-FEB-1997; US-806596.
PR 01-AUG-1997; US-904809.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI: 98-480805/41.
DR P-PSDB: W69389.
PT Novel human prostate specific tumour protein and fragments - useful
PT for detecting and treating prostate cancers
PS Claim 1; Page 116-117; 141pp; English.
CC This sequence represents a human prostate tumour specific gene, and can
CC be used in the method of the invention. The method is for detecting
CC prostate cancer comprises contacting a biological sample with an agent
CC able to bind an immunogenic portion of a prostate protein (such as
CC encoded by this sequence). An antibody which binds to an immunogenic
CC portion of the prostate protein, and the method can be used to detect,
CC monitor progression of, or treat prostate cancers. The antibody may
CC also be conjugated to a therapeutic agent for use in therapy of prostate
CC cancers.
SO Sequence 1119 BP; 248 A; 305 C; 282 G; 284 T;

Query Match 65.7%; Score 153.8; DB 1; Length 1119;
Best Local Similarity 93.1%; Pred. No. 3.4e-37;
Matches 161; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 1 acacagacccctgtctgcttaacgacctatcatcaagtggagcaatccgtgtccg 60
DB 209 ACAACAGACCCCTGTGCTGCTTAACGACCTCATGCTCATCAAGTTGACGAAATCCGTGTCG 268
QY 61 agcttgacacatcccgagacatcagcatgtctgcagtgccctacgcgagggaacctctt 120
DB 269 AGCTGACACCATCCGAGACATCAGCATTTGCTTCGACGTGCCCTACCGCGGGAACCTCTT 328
QY 121 gccctgttctggctgggtgtctgctggcgaaacgg 173
DB 329 GCCTCGTTTCTGGCTGGGGGTCTGCTGGCGAACGATGCTGATTCGATCCATCCAG 381

RESULT 15
V61253 standard; cDNA; 1119 BP.
AC V61253;
DT 06-JAN-1999 (first entry)
DE cDNA sequence of prostate tumour clone P703 splice variant DE14.
KW Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN MO9837093-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; US-03492.
PR 09-FEB-1998; US-020956.
PR 25-FEB-1997; US-806099.
PR 01-AUG-1997; US-904804.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI: 98-609886/51.
DR P-PSDB: W71873.
PT Polypeptides comprising immunogenic portions of prostate proteins -
PT used in a vaccine for the treatment of prostate cancer
PS Claim 3; Page 108-109; 130pp; English.
CC The present sequence is a new DNA which encodes an immunogenic portion
CC of a prostate tumour protein. The encoded immunogen, or the DNA itself,
CC can be used as a vaccine for the treatment of prostate cancer. The DNA
CC was identified by analysis of a substracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
CC tissue cDNA library.

Sequence 1119 BP; 248 A; 305 C; 282 G; 284 T;

Query Match 65.7%; Score 153.8; DB 1; Length 1119;
 Best Local Similarity 93.1%; Pred. No. 3.4e-37;
 Matches 161; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 1 acacagacccctgctgctgaacgacctcatgctcaagttggaagaaaccgtgtccg 60
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 209 ACAACAGACCCCTGCTGCTAACGACCTCATGCTCATCAAGTTGAGAGATCCGTGTCCG 268
 QY 61 agctcgaacacatccggaagcatcagcatgtcttcgcaagtgcctaccgcyggaactctt 120
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 269 AGTCTGACACCATCCGAGCATCATGCTTCTGAGTGCCCTACCGCGGGAACCTCTT 328
 QY 121 gctcgtttctggtggtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 173
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 329 GCCTCGTTCTGGGTGGGTGCTGCTGGGAGCATGCTGTGATTGCCATCCAG 381

Search completed: June 19, 2000, 18:55:38
 Job time: 4033 Sec

This Page Blank (uspto)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 19, 2000, 18:55:47 ; Search time 94.16 Seconds
(without alignments)
4307.151 Million cell updates/sec

Title: US-09-232-880-107
Perfect score: 1621
Sequence: 1 cgcacatgacacgcagggca.....aaaaaaaaaaaaaaaaaaaa 1621

Scoring table: IDENTITY_NUC
Gapop 10.0 ; Gapext 1.0

Number of hits satisfying chosen parameters: 623170

Minimum DB seq length: 0
Maximum DB seq length: 1000000

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database : N_Geneseq_36.*
Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1621	100.0	1621	V58584	Prostate tumour sp
2	1621	100.0	1621	V61199	Full length CDNA s
3	515	31.8	537	V58551	Prostate tumour s
4	515	31.8	537	V61189	CDNA sequence of p
5	406.6	25.1	773	V58481	5' fragment of pro
6	406.6	25.1	773	V61141	5' CDNA sequence o
7	403.2	24.9	793	V58510	3' fragment of pro
8	403.2	24.9	793	V61276	3' CDNA sequence o
9	400.2	24.7	816	V58480	3' fragment of pro
10	400.2	24.7	816	V61140	3' CDNA sequence o
11	248.2	15.3	1462	Q44447	Cephalosporin C g
12	234.8	14.5	5537	Q44448	Cephalosporin C g
13	67.8	4.2	2123	T59701	PTH-like peptide D
14	66.6	4.1	208	V09116	3' nucleotide sequ
15	65.2	4.0	4237	V61487	Human secreted pro
16	63.4	3.9	1172	O58659	Protein allergen o
17	62.8	3.9	1534	T15895	Human interleukin-
18	62.2	3.8	2094	X19489	Human secreted pro
19	62.2	3.8	2447	V54587	Human secretory pr
20	62	3.8	1474	T90174	Oil seed rape cyst
21	62	3.8	4061	V44867	Clone CT797_3 codi
22	61.2	3.8	2594	T02367	Melon aconitase cd
23	60.8	3.8	270	T89602	Hepatitis C virus
24	60.8	3.8	1733	V81394	Human tumour anti
25	60	3.7	1220	X04311	Human secreted pro
26	59.8	3.7	2339	O63892	Tomato acid invert
27	59.8	3.7	2339	T01339	Tomato acid invert
28	59.6	3.7	2634	X27062	S. tuberosum isom
29	59.6	3.7	1261	X04382	Human secreted pro
30	59.6	3.7	1641	T15758	Human interleukin-
31	59.4	3.7	7753	O56826	Normal virus stia
32	59.2	3.7	1558	T28255	Survival motor neu
33	59.2	3.7	1560	T18828	Human survival mot
34	59.2	3.7	1582	T18831	Human survival mot

35	59.2	3.7	1582	1	T28259	Survival motor neu
36	59.2	3.7	2001	1	T59700	PTH-like peptide D
37	59.2	3.7	2427	1	O04107	Human pro-urokinas
38	58.6	3.6	2233	1	V10120	Human retinoid rec
39	58.6	3.6	2277	1	O20360	Human pro-urokinas
40	58.6	3.6	6644	1	X33181	Base sequence of t
41	58.6	3.6	7372	1	X33182	Base sequence of t
42	58.6	3.6	7797	1	X33180	Cowpox virus bsr f
43	58.6	3.6	7996	1	X33184	Base sequence of t
44	58	3.6	1536	1	O94111	mml genomic DNA. T
45	58	3.6	2271	1	V84632	Human secreted pro

ALIGNMENTS

RESULT	ID	Sequence	Location/Qualifiers
V58584	V58584	standard; CDNA: 1621 BP.	
V58584	V58584	standard; CDNA: 1621 BP.	
AC	08-DEC-1998	(first entry)	
DE	Prostate tumour specific gene clone Fl-12.		
KW	Prostate tumour specific gene; human; prostate cancer; detection;		
OS	therapy; ss.		
OS	Homo sapiens.		
FT	Key	Location/Qualifiers	
FT	CDS	5..1153	
FT	CDS	/*tag= a	
PN	WO9837418-A2.		
PD	27-AUG-1998.		
PF	25-FEB-1998; U03690.		
PR	09-FEB-1998; US-904809.		
PR	25-FEB-1998; US-806596.		
PR	01-AUG-1997; US-904809.		
PA	(CORI-) CORIXA CORP.		
PI	Dillon DC, Xu J;		
DR	WPI: 98-480805/41.		
DR	P-PSDB: W69383.		
PT	Novel human prostate specific tumour protein and fragments - useful		
PT	for detecting and treating prostate cancers		
PS	Claim 1: Page 81-82; 141pp; English.		
CC	This sequence represents a human prostate tumour specific gene, and can		
CC	be used in the method of the invention. The method is for detecting		
CC	prostate cancer comprises contacting a biological sample with an agent		
CC	able to bind an immunogenic portion of a prostate protein (such as		
CC	encoded by this sequence). An antibody which binds to an immunogenic		
CC	portion of the prostate protein, and the method can be used to detect,		
CC	monitor progression of, or treat prostate cancers. The antibody may		
CC	also be conjugated to a therapeutic agent for use in therapy of prostate		
CC	cancers.		
SO	Sequence 1621 BP; 461 A; 330 C; 412 G; 418 T;		
Query Match 100.0%; Score 1621; DB 1; Length 1621;			
Best local similarity 100.0%; Pred. No. 0;			
Matches 1621; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	1	cgcacatgacacgcagggcaatcgtcatgagagctgctcgcgcctggccggccgctt	60
DB	1	CGCCATGGCAGCTCAGGAGCATCTCGGTCAATGAGAGCTGCTCGGCGCCGCCGCTT	60
QY	61	ctgtgctatgctctgctgctgctgctgctgctgctgctgctgctgctgctgctgct	120
DB	61	CTGTGCTATGCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT	120
QY	121	ccgctacgacgtgacgcctgctgctgctgctgctgctgctgctgctgctgctgctg	180
DB	121	CCGCTACGACGTAGCAGCCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	180
QY	181	gcccgggggagccgcgcgtgctgctgctgctgctgctgctgctgctgctgctgctg	240
DB	181	GCCGGGGGAGCCGCCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	240

```

OY 241 ctccgcgcggtgtcatgagaaactccagctggcccgagagatctgcagcgggaaaa 300
    |||
Db 241 cttccgcccgcgtgtcatgagaaactccagctggcccgagagatctgcagcgggaaaa 300
OY 301 tccaaggttatatgccaagcgtgagtgatgtggccaagtcagaaactctctgcggtt 360
    |||
Db 301 tcCaAGGcTtATtATtAGcCAGcGTgAGtTtGGcCAGtCAGGAACtTtCCGcGtT 360
OY 361 agctggccagatatacaactatctgctcttgcagtgctctctcaaaaatctgcagag 420
    |||
Db 361 AGctGGccAGATATCAcTAATtTtGGcTtTtGcAGcGTtTtCTCAAAAATtTtGCAGAG 420
OY 421 tgtgtgaagatccgtatgccccgtgaaatccctggcgtgacttgcgtggtggccttat 480
    |||
Db 421 TGGtGAGATCCGtATGCCCCGcGTGAATCTtGcCTCAcTtTtGcGTGcGTGcCTTAT 480
OY 481 gctgtgaatggcagttataatgagctcttcttgcagcagcagcctgccaagggcaggt 540
    |||
Db 481 GTtGcACTtGGcATtTtATtAGcCTtTtTtGACcGcACGcACTGcAAAGGcTCAAGT 540
OY 541 catgatgcaaatatggtggaaggaacagacataatcttctctctctggaagaaactca 600
    |||
Db 541 CATtGATGCAATATtGtGGAGAGACAGCATATtTAAGtTtTtTtCTtGtGGAATCTCA 600
OY 601 gaaatcgaagctctgtgggaagcactcgcagagcagaaactgttggatggtagagccttt 660
    |||
Db 601 GAAATCGAGtCTGtGGAGACcCTCGAGACAGAAcATGtTGAATGtGAGAGcACtTtT 660
OY 661 ctataagcacttaaggaaggaagcagatgggaaatctatgctgttggagaatataagaccca 720
    |||
Db 661 cTAATACGACTtTACAGAGAGcAGATGGGGAATtTCAcTGGcCTtTtGAGAGAAATGAAGcCCCA 720
OY 721 gctctacagcgtctgcatcaaaagcacttggactaaagctcatggaactctccaatcagat 780
    |||
Db 721 GTtCTAGAGcGTtGcTGAATCAAGAGcCTtGACtTAAGtCTATGACtTtCCCAATCAAT 780
OY 781 gagcattggaatctggtgccagaagaatgaaagaagtctgcagatgtaatttgaagaagaac 840
    |||
Db 781 GAGcATGATGATtTtGGcCAGAAATGAAGAAAGtTtGCAATGtATtTtGCAAAAGAAAGAC 840
OY 841 gaaagcagagtggtgtcaaatcttcttgcagcagatgctcgtgtgactccggttcttac 900
    |||
Db 841 GAAAGcAGAGtGtGTCAAAATCTtTtGAGGcACACATcCTGtGACtCCGcGTCTTAC 900
OY 901 tcttgaagaggtctgtcatcatcatcaacaagaagcgggctgcttaccacagtgga 960
    |||
Db 901 TTTtGAGAGAGtTtGTCTCATGATCAACACAGAGAGGGGcCTtTtATCACCAAGTGA 960
OY 961 ggaagcagagtgagccccgcgcctgcacctcgtctgtttaaaccaccccgacatcccttc 1020
    |||
Db 961 GGAGcAGAGcCTGAGcCCcCCcCTGcACCTGCTGtTtAAACACCCcAGcCATcCCCTTC 1020
OY 1021 tttaaaagagatctcttcatagagagaacacatgagagatcttgaagaatttggatt 1080
    |||
Db 1021 TTTCAAAAGGAGcCTtTtCATAGAGAGACACATGAGAGATtTtGAAGATtTtGGATT 1080
OY 1081 cagcgcgaagaagattatcagccttaactcagataaatacttgaagaatataaggtttaa 1140
    |||
Db 1081 CAGcCGGAGAGATtTtATcAGCTTAATCTCAGATtAAATtCTtGAAGATtTtAAAGTtAA 1140
OY 1141 agctagctcctaactctccagcccaagcctcaagtgaatttgaatactgtcaatagtg 1200
    |||
Db 1141 AGCTAGtCTTAACtTtCCAGcCCcAGcGCTCAAGtGAATtTtGAATtTtGCAATtTtCAATG 1200
OY 1201 taaggtatacacataactctgtatgtatgtgaaacatgagagagagatatacagtgctcta 1260
    |||
Db 1201 TAGAGtAAcATATCAATtTtATcATGAGAAACATGAGAGAAcAGTATtTtAGAGtTCTCTTA 1260
OY 1261 ccaactcaatcaagaagaagaattacagacactgattctcagatgatttgaattctttaa 1320
    |||
Db 1261 CCAcTCTtATtCAAAAGAAAGATtTtACAGAcTCTGATtTtTACAGtGATtTtAAATtTtTAA 1320
OY 1321 aatgttatcatagggccttcttgaattataaaacttgggtactataactaaatattggt 1380

```

```

Db 1321 AATGTTATCATATAGGcCTTtTtTATAAACTtTtGGTACTTATACtAAATtATAGT 1380
OY 1381 agttatctgcctccagttgtgtgatataattgttgataatgaattcttgcctata 1440
    |||
Db 1381 AGTtATtCTGcCTTCAcGtTtGCTtGATtATtTtTtGATtATtAGATtTtCTtGACTTATA 1440
OY 1441 ttctgaatgggtctctagtgaaagaagatgatatattcttgaagacatcgaatacattt 1500
    |||
Db 1441 TTTGAATGGGtTtTtAGGAAAAAGAAATGATtATtTtTtTAACACATCAATACATtT 1500
OY 1501 attaacactcttgattctacaaatgtagaaatgagaatgccaaatgtatgtgat 1560
    |||
Db 1501 ATTtACACTCTtTtGATtTtTACATGtAGAAATGAGAAATCCACAAATtTtATGtGAT 1560
OY 1561 aaaaagtcagtgaaacaaataaaaaataaaaaataaaaaataaaaaataaaaaa 1620
    |||
Db 1561 AAAAGTCAGtGAACAAAAAaAAAAAaAAAAAaAAAAAaAAAAAaAAAAAaAAAAA 1620
OY 1621 a 1621
    |||
Db 1621 A 1621

RESULT 2
V61199
ID V61199 standard; cDNA: 1621 BP.
AC V61199:
DT 06-JAN-1999 (first entry)
DE Full length cDNA sequence of prostate tumour clone F1-12.
KW Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN M09837093-A2.
PD 27-AUG-1998
PE 25-FEB-1998; U03492.
PR 09-FEB-1998; US-020956.
PR 25-FEB-1997; US-806099.
PR 01-AUG-1997; US-904804.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J.
DR WPI: 98-60986/51.
DR P-PSDB: W71867.
PT Polypeptides comprising immunogenic portions of prostate proteins -
PT used in a vaccine for the treatment of prostate cancer
PS Claim 3: Page 76-77; 130pp; English.
CC The present sequence is a new DNA which encodes an immunogenic portion
CC of a prostate tumour protein. The encoded immunogen, or the DNA itself,
CC can be used as a vaccine for the treatment of prostate cancer. The DNA
CC was identified by analysis of a subtracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
CC tissue cDNA library.
SQ Sequence 1621 BP; 461 A; 330 C; 412 G; 418 T;

Query Match 100.0%; Score 1621; DB 1; Length 1621;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1621; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 cgcacatggcactgacgagcactcgtcatgagctgtccggcctggcccgccggtt 60
    |||
Db 1 CGCCATGGcACTGcAGGAGcATCTGcTCAATGAGAcCTGcGGcCTGcCCcCGGcCGcCTT 60
OY 61 ctgtgcatgtgtctctgtgctgacttcggggcggtgtgtatcggttgacggccggcgtc 120
    |||
Db 61 CTGtGCTATGtGTCTGcCTGcTGAcCTTcGGGcGcGcGTGtGtAGcCTGcAGcCGcCCGcCTC 120
OY 121 ccgctacagacgttgagccgcttgagccgggcaagcgcctgagtgtgagacctgaagca 180
    |||
Db 121 CCGcTACAGAcGTtGAGcCGcCTtTtGGcCCcGGGcCAACcCTcCTGcTACtGcAGAcTGAAGCA 180
OY 181 gcgcggggagccgcgtgtcgtcggcgctctgtgcaagcgggtcggatgtgtcgtcggacc 240
    |||
Db 181 GCCcGGGgGAGcCCcCGcGTGcTGTGcGCGcCTGTGTGAACcGGcGAGtGTGcTGTGAGGCC 240

```

```

QY 241 ctcocgcccgtgtcaltgagaaactccagctggcccagagattctgcacgcygaa 300
DB 241 CTTCGCGCGGGTGTCAATGAGAACTCCAGCTGGCCAGAGATTTCGAGCGGGAAA 300
QY 301 tccaagacttattatgcaagctgagtgatgttgccagctcagaagctctgcggtc 360
DB 301 TCCAAGGCTTTTATGCGAGGCTGAGTGGAATTGGCCAGTACAGAACTTCGCGGTT 360
QY 361 agctggccagatatacaactatttggtcttgcttgcttgcttctcctcaaaatttgcaag 420
DB 361 AGCTGGCCAGATATCAACTATTGGCTTTTGGAGGTGTCTCTCAAAAATTGGCAGAG 420
QY 421 tggtagaagatccgtatgcccgcgttaactccctgcgtcactctgtgtgtgtgtcctat 480
DB 421 TGGTAGAAGATCCGTATGCCCGCTGAATCTCTGCTGCTGCTGCTGCTGCTGCTGCTTAT 480
QY 481 gctgtcactggcattataatgtctcttttgaccgcacacgcacgtgcaaggtcaggt 540
DB 481 GTGTGCACTGGGCAATTAAATGAGCTCTTTTGACCGCACACGCACTGCAAGGGTCAGGT 540
QY 541 catgtatgcaaatatgtgtggaagacagcagcagcagcagcagcagcagcagcagcagc 600
DB 541 CATTGATGCAAAATATGTTGGAAGAACAGCATATTTAAGTCTTCTTCTGGAAGAACTCA 600
QY 601 gaatcgcagctctgtggaagacacccctgcagacagacagcagcagcagcagcagcagc 660
DB 601 GAAATCGAGTGTGTGGAGACCTCTGAGAGACAGAACATGTTGGATGGTGGAGCAGCTTT 660
QY 661 ctatacgaactacaggaagacagcagcagcagcagcagcagcagcagcagcagcagcagc 720
DB 661 CTATACGACTTACAGAGACAGCAGATGGGGAATTCATGCTGTGTGAGCAATGAGACCCCA 720
QY 721 gttctcagagctgtctgatacaagagcttgagcagcagcagcagcagcagcagcagcag 780
DB 721 GTTCTACAGCTGTGATCAAAAGCCTTGATGATGATGATGATGATGATGATGATGATGAT 780
QY 781 gagcagatgattgtgcagagaagaagaagaagaagaagaagaagaagaagaagaagaaga 840
DB 781 GAGCATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 840
QY 841 gaagcagagctgtgtgtcaaatctttgacgcagcagcagcagcagcagcagcagcagc 900
DB 841 GAAGCAGAGCTGTGTCAAACTTTGACGGCAGACATGCTGTGTGACCTCGGTTCTGAC 900
QY 901 ttttgagagaggttgtctatcatatgatacaacaagaagcagcagcagcagcagcagc 960
DB 901 TTTTGAGAGAGGTTGTCTATCATGATCAACAAAGCAGGCGCTGTTATCACAGTGA 960
QY 961 gagcagagcgtgagccccccgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 1020
DB 961 GGAGCAGAGAGCTGAGCCCCCGCTGACCTCTGCTGTTAAACACCCAGCCATCCCTTC 1020
QY 1021 tttcaaaaggagctcttcatatgagagaacacacactgagagagatcttgaagaattg 1080
DB 1021 TTTCAAAAGGAGCTCTTTCATAGAGAACACACTGAGGAGTACTTGAAGATTGGATT 1080
QY 1081 cagccgcgaagaagattatcagcagcagcagcagcagcagcagcagcagcagcagcagc 1140
DB 1081 CAGCGCGCAAGAGATTATCAGCTTACCTGATTAATTAATTAATTAATTAATTAATTAATTA 1140
QY 1141 agctagcttcaacttcaagggccagcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 1200
DB 1141 AGCTAGCTTCACTTCAAGGCCAGCGCTCAAGTGAATTTGAATTAATTAATTAATTAATTA 1200
QY 1201 tagagtaacacataacatgtatgatagaaacacacacacacacacacacacacacacacac 1260
DB 1201 TAGAGTAACACATAACATTTGATGATGAAACATGAGAGACATATTATACAGTCTCCTCA 1260
QY 1261 ccaactcatacaagaagaatcacagactgtattctacagtgatgattgaattctctaa 1320
DB 1261 CCACTCTAATCAAGAAAGAAATTAACAGACTGTGATTACAGTGTGATGATTGAATTTAA 1320

```

```

QY 1321 aatgttatcatagggcttttgattataaaactttgggtactatactaaattatgt 1380
DB 1321 AATGTTATCAATTAGGGCTTTGATTTATTAACCTTGGTACTATCAATTAATATGAT 1380
QY 1381 agttattcgcctccagcttgctgataattgttgatattgaattcctgactata 1440
DB 1381 AGTTATTCTGCTTCCACTTGTGATTAATTTGTTGATTAATTAATTAATTAATTAATTA 1440
QY 1441 tttgaatgggttctaggaagaagaatgatatattcttgaagacacagcagcagcagc 1500
DB 1441 TTTGAATGGGTTCTAGGAAAGAAATGATTAATTTCTTAAGCAGCATGATTAATTAAT 1500
QY 1501 attacacacttgaattctacacatgtaagaatggaatgccaaattgtatgtat 1560
DB 1501 ATTACACTCTTGAATTGTACATGTAAGAAATGAGAAATGCCAAATTTGATGCTGAT 1560
QY 1561 aaagtcagtgaaacaaacaaacaaacaaacaaacaaacaaacaaacaaacaaacaaac 1620
DB 1561 AAAAGTCAGTGAAACAAACAAACAAACAAACAAACAAACAAACAAACAAACAAACAAAC 1620
QY 1621 a 1621
DB 1621 A 1621

RESULT 3
VS8551
ID VS8551 standard; cDNA: 537 BP.
AC VS8551;
DT 08-DEC-1998 (first entry)
DE Prostate tumour specific gene clone R1-2330.
KW Prostate tumour specific gene; human; prostate cancer; detection;
KW therapy; ss.
OS Homo sapiens.
PN M09837418-A2.
PD 27-AUG-1998.
PE 25-FEB-1998: U03690.
PR 09-FEB-1998: US-904809.
PR 25-FEB-1997: US-806596.
PR 01-AUG-1997: US-904809.
PA (CORI-) CORINA CORP.
PI Dillion DC, Xu J.
DR WPI: 98-480805/41.
PT Novel human prostate specific tumour protein and fragments - useful
PT for detecting and treating prostate cancers
PS Claim 1; Page 67; 141p; English.
CC This sequence represents a human prostate tumour specific gene, and can
CC be used in the method of the invention. The method is for detecting
CC prostate cancer comprises contacting a biological sample with an agent
CC able to bind an immunogenic portion of a prostate protein (such as
CC encoded by this sequence). An antibody which binds to an immunogenic
CC portion of the prostate protein, and the method can be used to detect,
CC monitor progression of, or treat prostate cancers. The antibody may
CC also be conjugated to a therapeutic agent for use in therapy of prostate
CC cancers.
SQ Sequence 537 BP; 185 A; 80 C; 98 G; 172 T;

Query Match 31.8%; Score 515; DB 1; Length 537;
Best Local Similarity 98.5%; Pred. No. 8.3e-98;
Matches 529; Conservative 0; Mismatches 7; Indels 1; Gaps 1;
QY 1036 tttcatagagaacacactgagagatacttgaagaatttgattcagccggaagat 1095
DB 1 TTTCATAGAGAAACACACTGAGAGATCTTGAAGAAATTTGATTCACCCCGAAGAGAT 60
QY 1096 ttataagcttaacacagtaaatcatcattgaaagtaagtaagtaagtaagtaagtaagta 1155
DB 61 TTATAGCTTAACTCAGTAATAATCAATTGAAAGTAATAAGTAATAAGTAAGTAAGTAAGT 120
QY 1156 tccagggccagcgtcaggtgaattgaattgaattgaattgaattgaattgaattgaattga 1215
DB 121 TCCAGGCCAGCGGCTCAAGTGAATTGAAATCTGATTTACAGTGTAGATGAACATCAATA 180

```

QY 1216 cattgtatgcatggaacaatgaggaacagatatacagtgctccacacctaacaaga 1275
DB 181 CATGTATGATGGAACATGAGGAACAGATATACAGTGTCTACCACTTAATCAAGA 240
QY 1276 aagaattacagactcgtatctacagtgatggaattcctaataatggtatcattag 1335
DB 241 AAGAAATTACAGACTCGATTTCTACAGTGAATGGAATTTGAAATGGAATCATTAG 300
QY 1336 gaccttgaattataaacttgggtactatacctaataatggtatcttcgccttc 1395
DB 301 GCGTTTGATTTAANAACCTTGGGTACTTACTAATTTGTAAGTATACGCTTC 360
QY 1396 cagttccttgatataatcttgatataatgaatccttgactataatcttgatggtct 1455
DB 361 CAGTTTCTTGATATATTGTTGATATTGAATTTGACTTATATTGTAAGTGGTCT 420
QY 1456 agtgaagaagaatgatatattcttgagaacatcgatataatattatcactctgat 1515
DB 421 ACTGAAAANAAGATGATATTTCTTGAGACATCGATATACATTATTATTTACACTTGAT 480
QY 1516 tctacaatgtagaagaatg-aggaaatgccacaattgtagtgatataaagtcacgt 1571
DB 481 TCTACATGTAGAAAATGAGGAATGCCCAATTGTATGTGATATAAAGTCCCGT 537

RESULT 4
V61189
ID V61189 standard; cDNA; 537 BP.
AC V61189:
DT 06-JUN-1999 (first entry)
DE CDNA sequence of prostate tumour clone R1-2330.
KW Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN MO9837093-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; US-903492.
PR 09-FEB-1998; US-020956.
PR 25-FEB-1997; US-806596.
PR 01-AUG-1997; US-904804.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI: 98-60986/51.
PT Polypeptides comprising immunogenic portions of prostate proteins -
PT used in a vaccine for the treatment of prostate cancer
PS Claim 3; Page 64; 130p; English.
CC The present sequence is a new DNA which encodes an immunogenic portion
CC of a prostate tumour protein. The encoded immunogen, or the DNA itself,
CC can be used as a vaccine for the treatment of prostate cancer. The DNA
CC was identified by analysis of a subtracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
CC tissue cDNA library.
SQ Sequence 537 BP; 185 A; 80 C; 98 G; 172 T;

Query Match 31.8%; Score 515; DB 1; Length 537;
Best Local Similarity 98.5%; Pred. No. 8.3e-98;
Matches 529; Conservative 0; Mismatches 7; Indels 1; Gaps 1;

QY 1036 tttcatgaggaacacactgagagatcttgaaagtgttgatcgccggcgaagat 1095
DB 1 TTTCATGAGGAACACCTGAGGAGATCTTGAAGAAATTTGGATTCCGCCGAAGAGAT 60
QY 1096 ttatcagcttaactcagataaatacatctgaagtaagtaaaactagctcactac 1155
DB 61 TTATCAGCTTAACCTACAGATAAATCATTTGAAGTAAGTAAGTAAGTAAGTAAGT 120
QY 1156 tccaagccacagcctcaagtgaattgaatactgcatcttcaagtgtagtaacacataa 1215
DB 121 TCCAGGCCCGCTCAAGTGAATTTGAATTTGCAATTTACAGTGTAGTAACACATAA 180
QY 1216 catgtatgtagaagaacagtaggaacatatacagtgctccacacctaacaaga 1275

DB 181 CATGTATGATGGAACATGAGGAACAGATATACAGTGTCTACCACTTAATCAAGA 240
QY 1276 aagaattacagactcgtatctacagtgatggaattcctaataatggtatcattag 1335
DB 241 AAGAAATTACAGACTCGATTTCTACAGTGAATGGAATTTGAAATGGAATCATTAG 300
QY 1336 gaccttgaattataaacttgggtactatacctaataatggtatcttcgccttc 1395
DB 301 GCGTTTGATTTAANAACCTTGGGTACTTACTAATTTGTAAGTATACGCTTC 360
QY 1396 cagttccttgatataatcttgatataatgaatccttgactataatcttgatggtct 1455
DB 361 CAGTTTCTTGATATATTGTTGATATTGAATTTGACTTATATTGTAAGTGGTCT 420
QY 1456 agtgaagaagaatgatatattcttgagaacatcgatataatattatcactctgat 1515
DB 421 ACTGAAAANAAGATGATATTTCTTGAGACATCGATATACATTATTATTACACTTGAT 480
QY 1516 tctacaatgtagaagaatg-aggaaatgccacaattgtagtgatataaagtcacgt 1571
DB 481 TCTACATGTAGAAAATGAGGAATGCCCAATTGTATGTGATATAAAGTCCCGT 537

RESULT 5
V58481/C
ID V58481 standard; cDNA; 773 BP.
AC V58481:
DT 08-DEC-1998 (first entry)
DE 5' fragment of prostate tumour specific gene F1-12.
KW Prostate tumour specific gene; human; prostate cancer; detection;
KW therapy; ss.
OS Homo sapiens.
PN MO9837418-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; US-903690.
PR 09-FEB-1998; US-904809.
PR 25-FEB-1997; US-806596.
PR 01-AUG-1997; US-904809.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI: 98-480805/41.
PT Novel human prostate specific tumour protein and fragments - useful
PT for detecting and treating prostate cancers
PS Claim 1; Page 35-36; 141p; English.
CC This sequence represents a human prostate tumour specific gene, and can
CC be used in the method of the invention. The method is for detecting
CC prostate cancer comprises contacting a biological sample with an agent
CC able to bind an immunogenic portion of a prostate protein (such as
CC encoded by this sequence). An antibody which binds to an immunogenic
CC portion of the prostate protein, and the method can be used to detect,
CC monitor progression of, or treat prostate cancers. The antibody may
CC also be conjugated to a therapeutic agent for use in therapy of prostate
CC cancers.
SQ Sequence 773 BP; 154 A; 242 C; 162 G; 197 T;

Query Match 25.1%; Score 406.6; DB 1; Length 773;
Best Local Similarity 98.6%; Pred. No. 2e-75;
Matches 409; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 615 ggaagacactcgaagacagaacatcttgatgttggaacaccttctatacgaactaca 674
DB 415 GGGCCCCCCTCGAGGACAGACATGTGGATGTGGAGCACTTTCTATACACTTACA 356
QY 675 ggaacagatggtgggaattcattgctgtggaacatagaaccagctctacagctgc 734
DB 355 GGACAGCAGATGGGAAATTCATGCTTTGAGCAATAGAACCCCACTTCTAGAGACTGC 296
QY 735 tgatcaagaagacttggaactaaagtctgataaacttccaatcgaagtagagatgatt 794
DB 295 TGATCAAGAAGANNTTGAATTAAGTCTGATGAATCTCCCAATCGAGATGATGATT 236
QY 795 ggcagagaatgaagaagaagtttcagatgtattctcaagaagaagcgaagcagatggt 854

Db 235 GGCAGAAATGAAGAGAGTTTGCAGATGATTTGCAAAAGACGAGAGAGTGT 176
QY 855 gtcaatctttgagcgcagatgcctgtgtgactccggtctgacttttgaagagtg 914
Db 175 GTCAATCTTTGAGCGGCACATGCTGTGACTCCGGTTCTGACTTTTGAAGAGTTG 116
QY 915 ttcatcatgatacaacaagaagcgggctgttataccagtgagagagagctga 974
Db 115 TTCAATCATGATCACAAGAGAGCGGGCTGTTTATCACCAGTAGAGAGAGAGCTGA 56
QY 975 gcccccgcctgcacctctgtctgttaaacacccagccatcccttcttcaaaag 1029
Db 55 GCCCCCGCCCTGCACCTCTGCTTTAAACCCAGCCATCCCTTCTTCAAAAG 1

RESULT 6

V61141/c
V61141 standard; cDNA; 773 BP.

DI 06-JAN-1999 (first entry)
DE 5' cDNA sequence of prostate tumour clone Fl-12.
KM Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN WO9837093-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; U03492.
PR 09-FEB-1998; US-020956.
PR 25-FEB-1997; US-806099.
PR 01-AUG-1997; US-904804.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J.
DR WPI: 98-609886/51.
PT Polypeptides comprising immunogenic portions of prostate proteins -
used in a vaccine for the treatment of prostate cancer
PS Claim 3; Page 35; 130pp; English.
CC The present sequence is a new DNA which encodes an immunogenic portion
of a prostate tumour protein. The encoded immunogen, or the DNA itself,
can be used as a vaccine for the treatment of prostate cancer. The DNA
CC was identified by analysis of a subextracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
CC tissue cDNA library.
SQ Sequence 773 BP; 154 A; 242 C; 162 G; 197 T;

Query Match

Local Similarity 25.1%; Score 406.6; DB 1; Length 773;
tches 409; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 615 ggaagacacccgcagagacagacatgttgatgtgtgagacaccccttatacagattaca 674
Db 415 GGGCCCCCTCGAGAGACAGAACATGTTGGATGTGAGACACCTTCTTACGATTTACA 356
QY 675 ggaacagatgtygggaattcatgtgtgttgagcaatagaaccacagttctagaagctgc 734
Db 355 GCAGACGAGATGGGGAATTAATGCTGTGAGCAATAGAACCCAGTCTACGAGCTGC 296
QY 735 tgatcaaaagagcttgatgaagctgtatgaacttcccaacagatggagcatgatgtatc 794
Db 295 TGATCAAAAGGNNMGATTAAGTGTGATGAACCTCCCAATCAGATGAGCATGAGATGATT 236
QY 795 ggcagaataaagaagaagatttgacatgtatcttgcacaagaagaagcagaagtggt 854
Db 235 GGCAGAAATGAAGAGAGTTTGCAGATGATTTGCAAAAGACGAGAGAGTGT 176
QY 855 gtcaatctttgagcgcagatgcctgtgtgactccggtctgacttttgaagagtg 914
Db 175 GTCAATCTTTGAGCGGCACATGCTGTGACTCCGGTTCTGACTTTTGAAGAGTTG 116
QY 915 ttcatcatgatacaacaagaagcgggctgttataccagtgagagagagctga 974
Db 115 TTCAATCATGATCACAAGAGAGCGGGCTGTTTATCACCAGTAGAGAGAGAGCTGA 56

QY 975 gcccccgcctgcacctctgtctgttaaacacccagccatcccttcttcaaaag 1029
Db 55 GCCCCCGCCCTGCACCTCTGCTTTAAACCCAGCCATCCCTTCTTCAAAAG 1

RESULT 7

V58510
V58510 standard; cDNA; 793 BP.

AC V58510;
DI 08-DEC-1998 (first entry)
DE 3' fragment of prostate tumour specific gene K1-48.
KM Prostate tumour specific gene; human; prostate cancer; detection;
therapy; ss.
OS Homo sapiens.
PN WO9837418-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; U03690.
PR 09-FEB-1998; US-904809.
PR 25-FEB-1997; US-806596.
PR 01-AUG-1997; US-904809.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J.
DR WPI: 98-480805/41.
PT Novel human prostate specific tumour protein and fragments - useful
PT for detecting and treating prostate cancers
PS Claim 1; Page 50; 141pp; English.
CC This sequence represents a human prostate tumour specific gene, and can
be used in the method of the invention. The method is for detecting
CC prostate cancer comprises contacting a biological sample with an agent
CC able to bind an immunogenic portion of a prostate protein (such as
CC encoded by this sequence). An antibody which binds to an immunogenic
CC portion of the prostate protein, and the method can be used to detect,
CC monitor progression of, or treat prostate cancers. The antibody may
CC also be conjugated to a therapeutic agent for use in therapy of prostate
CC cancers.
SQ Sequence 793 BP; 184 A; 200 C; 189 G; 200 T;

Query Match

Best Local Similarity 24.9%; Score 403.2; DB 1; Length 793;
Matches 408; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 630 gacagaacatgttgatgtgagacaccccttctatacagattacaagacagatggg 689
Db 1 GACAGAAATGATGTGATGTGAGACACCTTCTTATACGACTTACAGAGACAGATGGG 60
QY 680 aattatgctgtgtgagacaaatagaaccacagttctacagagctgtgatacaagagcttg 749
Db 61 AATCATGCTGTGAGACCAATANAAACCCAGTCTTACGAGCTGCTGATCAAAAGACTTG 120
QY 750 gactaaagctgatagaattcccaatcagatgagcatgatgttgagccaaatagaaga 809
Db 121 GACTTAAAGTCTGATGAATCTCCCAATCAGATGAGATGATGATGGCCACAAATAGANA 180
QY 810 agaagttgcagatgatttcgaagaagaagcagaagtggtgtcaaatcttgagc 869
Db 181 AGAAGTTTGCAGATGATTTTGCAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 240
QY 870 gacagatgctgtgtgacacccggtctgacttttgaggaaggtgtgtatcatgatgaca 929
Db 241 GCACAGATGCTGTGTGACTCCGGTTCTGACTTTGAGAGAGTTGTTTATCATGATCACA 300
QY 930 acaagaagcaggggtcgtttataccagtgagagcagaagtgagagagagagagagag 989
Db 301 ACAAGAAGCGGGGCTGTTTATCACCANTGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 360
QY 990 ctctgctgttaaacacccagccatcccttcttcaaaagagatcccttataagagagac 1049
Db 361 CTCTGCTTTTAAACCCAGCCATCCCTTCTTCAAAAGGATCCACTACTTCTAGAGC 420

RESULT 8

V61276

ID V61276 standard; cDNA: 793 BP.
 AC V61276:
 DT 06-JAN-1999 (first entry)
 DE 3' cDNA sequence of prostate tumour clone KI-48.
 KW Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
 OS Homo sapiens.
 PN WO9837093-A2.
 PD 27-AUG-1998.
 PF 25-FEB-1998: U03492.
 PR 09-FEB-1998: US-020956.
 PR 25-FEB-1997: US-806099.
 PR 01-AUG-1997: US-904804.
 PA (CORI-) CORIXA CORP.
 PI Dillon DC, Xu J;
 PI WPI: 98-609886/51.
 PT Polypeptides comprising immunogenic portions of prostate proteins -
 used in a vaccine for the treatment of prostate cancer
 PS Claim 12: Page 48-49; 130pp; English.
 CC The present sequence is a DNA which encodes an immunogenic portion
 of a prostate tumour protein. The encoded immunogen, or the DNA itself,
 can be used as a vaccine for the treatment of prostate cancer. The DNA
 was identified by analysis of a subtracted cDNA library obtained by
 CC subtracting a prostate tumour cDNA expression library with a normal
 CC tissue cDNA library.
 CC Sequence 793 BP: 184 A: 200 C: 189 G: 200 T:

Query Match 24.9%; Score 403.2; DB 1; Length 793;
 Best Local Similarity 97.1%; Pred. No. 1e-74;

Matches 408; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 630 gacagaacatgttgatgagtgagacaccttctatagacattacaggaacagatggg 689
 DB 1 GACAGAACATGTTGATGAGTGAGACACTTCTATACGACTTACAGACAGCAGATGGG 60
 QY 690 aattcagtcctgttgagagaatagaaacccagttctacagagctgcagatcaaggatctg 749
 DB 61 AATTCATGCTGTGAGAGCAATNAAACCCAGTTCTTACAGAGCTGCTGATCAAGAGACTTG 120
 QY 750 gactaaagtcagtaacttcccatcagaatgagacatgagatgagtcgacgaataaga 809
 DB 121 GACTAAAGTCGTATGAACTTCCCAATCAGATGAGATGATGATGGCCAGAAATGAANA 180
 QY 810 aagaagttcagatgatttgcagaagaagcagagcagatggtgtcgaattcttgaagc 869
 DB 181 AAGAAGTTTCAGATGATTTGCAAGAAGACGAAAGCAGAGTGTGTCAAATCTTGAAG 240
 QY 870 gacacagatcctgtgagactcgggtctgactttagaaggtgtgtctatcagacaca 929
 DB 241 GACACAGATCCTGTGTGACTCCGATTCTGACTTTTGAAGAGGTTGTCATCATGATCACA 300
 QY 930 acaagaagaaggggctcgtttatcacagcagtaagagcagagcgtgagcccgccgtcac 989
 DB 301 ACAANAAGGGGCTGTTTATCACCANTGAGAGCAGACGAGACCCCGCCCTGCAC 360
 QY 990 cctctgctttaaaccacccagccatccctcttcaaaagggaatccttcataggaagc 1049
 DB 361 CTTCTGCTGTTAAACACCCAGCCATCCCTTCTTCAAAAGGATCCACACTCTCTAGAG 420

RESULT 9

V58480
 ID V58480 standard; cDNA: 816 BP.

AC V58480:
 DT 08-DEC-1998 (first entry)
 DE 3' fragment of prostate tumour specific gene FI-12.
 KW Prostate tumour specific gene; human; prostate cancer; detection;
 OS Homo sapiens.
 PN WO9837418-A2.
 PD 27-AUG-1998.
 PF 25-FEB-1998: U03690.
 PI WPI: 98-609886/51.
 PT Polypeptides comprising immunogenic portions of prostate proteins -
 used in a vaccine for the treatment of prostate cancer
 PS Claim 3; Page 130pp; English.

PR 25-FEB-1997: US-806596.
 PR 01-AUG-1997: US-904809.
 PA (CORI-) CORIXA CORP.
 PI Dillon DC, Xu J;
 PI WPI: 98-480805/41.
 PT Novel human prostate specific tumour protein and fragments - useful
 for detecting and treating prostate cancers
 PS Claim 1; Page 35; 141pp; English.
 CC This sequence represents a human prostate tumour specific gene, and can
 be used in the method of the invention. The method is for detecting
 CC prostate cancer comprises contacting a biological sample with an agent
 able to bind an immunogenic portion of a prostate protein (such as
 CC encoded by this sequence). An antibody which binds to an immunogenic
 CC portion of the prostate protein, and the method can be used to detect,
 CC monitor progression of, or treat prostate cancers. The antibody may
 CC also be conjugated to a therapeutic agent for use in therapy of prostate
 CC cancers.
 CC Sequence 816 BP: 189 A: 205 C: 208 G: 201 T:

Query Match 24.7%; Score 400.2; DB 1; Length 816;
 Best Local Similarity 98.1%; Pred. No. 4.3e-74;

Matches 405; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 636 acatgttgagtgagagacaccttctatagacattacaggaacagatgggaattca 695
 DB 5 AATGTTGATGATGAGAGCACCTTCTATACGACTTACAGACAGACAGATGGGAATTCA 64
 QY 696 tggctgttgagacatagaaacccagttctacagacgtctgttcaaaaggacttgactaa 755
 DB 65 TGGCTGTTGAGCAATAGAACCCAGTTCTTACGAGCTGTGATCAAGAGACTTGGACTTAA 124
 QY 756 agctgatgaacttcccatcagaatgagatgagattggcagagaataagaaagaagt 815
 DB 125 AGCTGATGAATCTTCCATCATCAGATGAGATGATGATGGCCAAATGAAGAAAGACT 184
 QY 816 ttgcagatgatttgcagaagaagcagagtgatgagtgatgagtgatgagtgagtgag 875
 DB 185 TTGCAGATGATTTTCAAGAAGAGAGAGAGAGAGAGTGTGTCAAATCTTGAAGGACAG 244
 QY 876 atgcccgtgtgagctcgggtctgactttagaagagtggttcatatgatacacaaga 935
 DB 245 ATGCCGTGTGACTCCGTTGACTTTTGAAGAGAGTGTTCATCATGATCAACAAGG 304
 QY 936 aacgggagctcgtttatcacagcagtaagcagagcgtgagcccgccctgacacttgc 995
 DB 305 AACGGGCTGCTTATCACCATGAGACGACGAGCTGAGCCCCCGCCCTGCACCTTTC 364
 QY 996 tgttaaacacccacagccatcccttctcaaaaggatccttcataggaagaa 1048
 DB 365 TGTAAACACCCAGCCAGCATCCCTTCTTCAAAAGGATCCACTAGTTCTAGAA 417

RESULT 10

V61140
 ID V61140 standard; cDNA: 816 BP.

AC V61140:
 DT 06-JAN-1999 (first entry)
 DE 3' cDNA sequence of prostate tumour clone FI-12.
 KW Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
 OS Homo sapiens.
 PN WO9837093-A2.
 PD 27-AUG-1998.
 PF 25-FEB-1998: U03492.
 PR 09-FEB-1998: US-020956.
 PR 25-FEB-1997: US-806099.
 PR 01-AUG-1997: US-904804.
 PA (CORI-) CORIXA CORP.
 PI Dillon DC, Xu J;
 PI WPI: 98-609886/51.
 PT Polypeptides comprising immunogenic portions of prostate proteins -
 used in a vaccine for the treatment of prostate cancer
 PS Claim 3; Page 35; 130pp; English.

CC The present sequence is a new DNA which encodes an immunogenic portion
CC of a prostate tumour protein. The encoded immunogen, or the DNA itself,
CC can be used as a vaccine for the treatment of prostate cancer. The DNA
CC was identified by analysis of a subtracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
CC tissue cDNA library.
SQ Sequence 816 BP; 189 A; 205 C; 208 G; 201 T;

Query Match 24.7%; Score 400.2; DB 1; Length 816;
Best Local Similarity 98.1%; Pred. No. 4,3e-74;
Matches 405; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 636 acatttgatgagtgagacaccttctatacgaactacagagagagagtgaggaattca 695
DB 5 AATATGTGGATGGTGGAGCACCCTTTCTATACGACTTACAGAGAGAGAGTGGGGAATTCA 64
QY 696 tggctgttgagcaatagagaccacagttctacgaagctgctgatacaaaagacttgagctaa 755
DB 65 TGGCTGTGGAGCAATAGAACCCCAAGTCTACGAGCTGCTGATCAAGAGACTTGGACTTAA 124
QY 756 actctgataaacttcccaatcagatgagatgagatgagcgaagaatgaagaagaat 815
DB 125 ACTCTGATGAATCTCCCAATCAGATGAGCATGATGATGGCCGAAATGAAGAAAGAACT 184
QY 816 ttgcagatgatttgcagaagaagacgaagagtggtgtcaaatctttgacagcagag 875
DB 185 TTGCAGATGATTTTGCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 244
QY 876 atgctgttgagacccggttctgacttttgagagagtggttctatcagatcaacaagaag 935
DB 245 ATGCTGTGTGACTCGGTTCTGACTTTGAGAGAGTGTGTCATGATCAACAGAGAG 304
QY 936 aacggggtcgtttatcaccagtgagagagagagagagagagagagagagagagagag 995
DB 305 AACGGGTCGTTTATACACAGTGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 364
QY 996 tcttaaacacccacgacatccttcttcaaaagagatccttcatagaagaa 1048
DB 365 TCTTAAACACCCAGCATCCCTTTCTTCAAAAGGATCCTAGTTTGAAG 417

RESULT 11

ID 044447 standard; cDNA to mRNA; 1462 BP.
AC 044447, 30-SEP-1994 (first entry)
T Cephalosporin C cDNA fragment.
K Cephalosporin C; A. crisogenum; biosynthesis; fermentation; ss.
OS Acromonium chrysogenum.
FH Key location/Qualifiers
FI cds 52.1203
FT /tag= a /product= Cephalosporin C
PT J06038763-A.
PN 15-FEB-1994.
PD 12-MAR-1993; 077367.
PR 13-MAR-1993; JP-088418.
PA (ASAH) ASAH CHEM IND CO LTD.
DR MPI; 94-094831/12.
DR P-PSDB; R49827.
PT A DNA fragment contg. a gene used in the bio-synthesis of
PT cephalosporin C - used to produce recombinants with improved
PT biosynthesis of cephalosporin C
PS Claim 4; Page 12-13; 19pp; Japanese.
CC The sequences given in 044446-47 encode the cephalosporin C gene and
CC were isolated from A. crisogenum. These gene fragments may be used
CC in the biosynthesis of cephalosporin C and in the production of A.
CC crisogenum strains with improved cephalosporin C fermentation
CC capabilities.
SQ Sequence 1462 BP; 272 A; 426 C; 482 G; 282 T;

Query Match 15.3%; Score 248.2; DB 1; Length 1462;
Best Local Similarity 57.4%; Pred. No. 1.1e-42;
Matches 511; Conservative 0; Mismatches 368; Indels 12; Gaps 3;

QY 17 ggcattcgatgagagagcttccgagcctgagcccgagccgcttctgtctatgctcgt 76
DB 82 GGCAGCTTGTGTAGAGCTCCCGGGGCTAGCCAGGCCCATCTGTGGCATGCTCTTG 141
QY 77 gctgaactggggcggtgtgtagcgtgtgagccgagccgagccgagccgagcagcgtgagc 136
DB 142 GCAAGACTATGCGCCCTCACTACTCCGATCGACGAGACCCGATCCC---CAAGGGGGAC 198
QY 137 cgtctggcgggggagagcgcgtcgtatgctgagcacttgaagcagcgcggggagcgcgc 196
DB 199 GTCCTGGCAGGAACAAGTCGTCATCTGATCGATGAGACTTGAACATCCGCCCTCACGCAAG 258
QY 197 gtgctggcggtctgtgcaagcgtgtgagatgtgtgtgtgagcccttccgcggtgtc 256
DB 259 GTGCTCTCTCCATCCTGTCGCCGCGGAGCTGCTCATGACCCGTTCCGGCCGCGCTC 318
QY 257 atgagaaactcagctgtgccc---cagagatctgcagcgggaaatccaaagcctatt 313
DB 319 CTGGAGCTGTGGGCTCTCCCCACAGAGTCTTCTCAAGGCGAATCCGCTGTG 378
QY 314 tatccagagctgagtgatgttgccagcagtcaggaagccttctgcggttgaagtcagcagat 373
DB 379 GTGCGCCGCTCACCGGCTTCCGCGAGATGGCACTACAGACATGGCAGGCTATGAT 438
QY 374 atcaactattgcttgcagtggttctcctcaaaaattggcagaagtgtagaagtcgcg 433
DB 439 ATCAATACCTGCGCGTGTGTCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 498
QY 434 tatgcccgtgaatctcctgtgacttctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 493
DB 499 TTCCCGCCGCGCAACATCTCTCGGCACTTTCGCGGAGGGGGGCGCAATGCTGCTGCTG 558
QY 494 attaatggtccttcttgacgcagcagcagcagcagcagcagcagcagcagcagcagcagc 553
DB 559 ATTCTCTGCGCTGCTGATCGCGGCGGATGCCACGAGGGGCTTGGCAGGCTCTGACGGCCAAC 618
QY 554 atggtggaagagacagcatatttaagttcttctgtgtggaagacacagcagcagcagcagc 613
DB 619 ATGATGAGAGGGGTCTGATGCTGAGGAGATGCGCGCTGCGGCAAGAGGCCCTTC 678
QY 614 tgggaagcacttcgagagacacatgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 673
DB 679 TGGGGTTCCCGCGGGGCGAGATGCTCGAGCGGAGGGGTGCCCTGTGATGCGACATAC 738
QY 674 aggaca-----gcagatggggaattcatgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 727
DB 739 CGGACAAAGAGACCCCGCGGGAATGATGAGCGCGGTGGAGCGCTGAGGCTCATCTTCAC 798
QY 728 gagctgtgatcaaaagacttgactaaagttctgtatgaacttcccaatcagatgaagcagc 787
DB 799 GAGGTCTGCTGTGAGAGTCTGGGCGCTGAGACAGAGACCTGCTCCCGGGAGGATAG 858
QY 788 gatgatgtgcccagaatgagaagaagagtttgcagatgtatttgcagaagaagcagaagca 847
DB 859 GCCAATTGGCCAGACTGAGGCGGCTATTCAGAGCAAAATTTGGCGAGAGAGCGCGCAC 918
QY 848 gattgtgtcaaatcttgaagcagagatgctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 898
DB 919 GAGTGGCGGAGGTCTTTACGCGGAGGATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 969

RESULT 12

ID 044448 standard; DNA; 5537 BP.
AC 044448; 30-SEP-1994 (first entry)
DT Cephalosporin C gene.
KW Cephalosporin C; A. crisogenum; biosynthesis; fermentation; ss.
OS Acromonium chrysogenum.

35	59.2	3.7	1582	1	T28259	Survival motor neu
36	59.2	3.7	2001	1	T59700	PTH-like peptide D
37	59.2	3.7	2427	1	Q04107	Human pro-urokinas
38	58.6	3.6	2233	1	V10120	Human retinoid rec
39	58.6	3.6	2377	1	Q20360	Human pro-urokinas
40	58.6	3.6	6644	1	X33181	Base sequence of t
41	58.6	3.6	7372	1	X33182	Base sequence of t
42	58.6	3.6	7797	1	X33180	Cowpox virus bsr f
43	58.6	3.6	7996	1	X33184	Base sequence of t
44	58	3.6	1536	1	Q94111	mML genomic DNA. T
45	58	3.6	2271	1	V84632	Human secreted pro

ALIGNMENTS

RESULT 1
V58584
ID V58584 standard; cDNA; 1621 BP.
AC V58584;
DT 08-DEC-1998 (first entry)
DE Prostate tumour specific gene clone F1-12.
KW Prostate tumour specific gene; human; prostate cancer; detection;
KW therapy; ss.
OS Homo sapiens.
FH Key Location/Qualifiers
FT CDS 5..1153
FT /*tag= a
PN WO9837418-A2.
PD 27-AUG-1998.
PF 25-FEB-1998; U03690.
PR 09-FEB-1998; US-904809.
PR 25-FEB-1997; US-806596.
PR 01-AUG-1997; US-904809.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI; 98-480805/41.
DR P-PSDB; W69383.
PT Novel human prostate specific tumour protein and fragments - useful
PT for detecting and treating prostate cancers
PS Claim 1; Page 81-82; 141pp; English.
CC This sequence represents a human prostate tumour specific gene, and can
CC be used in the method of the invention. The method is for detecting
CC prostate cancer comprises contacting a biological sample with an agent
CC able to bind an immunogenic portion of a prostate protein (such as
CC encoded by this sequence). An antibody which binds to an immunogenic
CC portion of the prostate protein, and the method can be used to detect,
CC monitor progression of, or treat prostate cancers. The antibody may
CC also be conjugated to a therapeutic agent for use in therapy of prostate
CC cancers.
SQ Sequence 1621 BP; 461 A; 330 C; 412 G; 418 T;

Query Match 100.0%; Score 1621; DB 1; Length 1621;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1621; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	cgccatggcactgcagggcatctcggtcatggagctgtccggcctggccccgggcccgtt	60
Db	1	CGCCATGGCACTGCAGGGCATCTCGGTCTATGGAGCTGTCCGGCCTGGCCCCGGGCCGTT	60
Qy	61	ctgtgctatggtcctggctgacttcggggcgcgctgtggtacgctggaccggccccggctc	120
Db	61	CTGTGCTATGGTCCTGGCTGACTTCGGGGCGCGTGTGGTACGCGTGGACGGCCCCGGCTC	120
Qy	121	ccgctacgacgtgagccgcttggggccggggcaagcgctcgcctagtgtgctggacctgaagca	180
Db	121	CCGCTACGACGTGAGCCGCTTGGGCCGGGGCAAGCGCTCGCTAGTGTGACCTGAAGCA	180
Qy	181	gccgcgggggagccgcccgtgctgcggcgctgtgtgcaagcggtcggatgtgtgctggagcc	240
Db	181	GCCGCGGGGAGCCGCCGTGCTGCGGCGTCTGTGCAAGCGGTGCGATGTGCTGAGGCC	240

This Page Blank (uspto)

Qy	241	ccccgcgcgggtgtccatggaagaacccacgtgcccagaaggtcttcgaagcggggaaa	3000
Db	241	cttccccccgggtgtcatgagaaactccacgtg6ggcccaagattctgcagccgggaaa	3000
Qy	301	tccaaaggtctatctatgcacaggtctgagtgatcttggccagtcagaagactcttcggtt	3600
Db	301	tccaaaggtctattatgacaggtctgagtgatcttggccagtcagaagactcttcggtt	3600
Qy	361	agctggccagatatacaactattggctttgcaagtgctctccaaaatgvcagaag	4200
Db	361	agctggccagatatacaactattggctttgcaagtgctctccaaaatgvcagaag	4200
Qy	421	tggtgagaatccctgatgccccgcgtgaacatccctcggcagactctggtgtgtgtctat	4800
Db	421	tggtgagaatccctgatgccccgcgtgaacatccctcggcagactctggtgtgtgtctat	4800
Qy	481	gtgtgactgvggcattataatgagctcttttgaccgcacacgcctacacaaggtcaggt	5400
Db	481	gtgtgactgvggcattataatgagctcttttgaccgcacacgcctacacaaggtcaggt	5400
Qy	541	catgatgcaaaataagtgvggaaggaacagcatatttaagttcttctgtggaacctca	6000
Db	541	catgatgcaaaataagtgvggaaggaacagcatatttaagttcttctgtggaacctca	6000
Qy	601	gaatccaggtctgtgtggaagacactctgagaacagaacatgttgatgtgagcaccttt	6600
Db	601	gaatccaggtctgtgtggaagacactctgagaacagaacatgttgatgtgagcaccttt	6600
Qy	661	ctatacgacttacaggaacagacagatggggaattcatatgctgtgttgagcaatagaaccca	7200
Db	661	ctatacgacttacaggaacagacagatggggaattcatatgctgtgttgagcaatagaaccca	7200
Qy	721	gttctacagactgtctgatacaaaagacttggactaaagtctgatatgaacttcccaatcagat	7800
Db	721	gttctacagactgtctgatacaaaagacttggactaaagtctgatatgaacttcccaatcagat	7800
Qy	781	gagcgtgataatattggccagaaatgaagaagaagtcttgcagatgattttgcaagaagac	8400
Db	781	gagcgtgataatattggccagaaatgaagaagaagtcttgcagatgattttgcaagaagac	8400
Qy	841	gaagcagagatggtgtcacaactctcttgcagcagacagatgacctgtgtacccggtctgac	9000
Db	841	gaagcagagatggtgtcacaactctcttgcagcagacagatgacctgtgtacccggtctgac	9000
Qy	901	ttttgaggaaggttgttcatcatcatgatacaacaagaagaaacgggggtctgttatccacagta	9600
Db	901	ttttgaggaaggttgttcatcatcatgatacaacaagaagaaacgggggtctgttatccacagta	9600
Qy	961	ggagcagagagctgtgcccccgccctctgactctctgtgttaacacccacagccatcccttc	10200
Db	961	ggagcagagagctgtgcccccgccctctgactctctgtgtgttaacacccacagccatcccttc	10200
Qy	1021	tttcaaaagagatcccttctatagagaacacactctggagagataactcttgaagaatttgagtt	10800
Db	1021	tttcaaaagagatcccttctatagagaacacactctggagagataactcttgaagaatttgagtt	10800
Qy	1081	cagcgcggaagagatattatcagcttcaactcagaataaatcatctgaaagatgaatgaatlaa	11400
Db	1081	cagcgcggaagagatattatcagcttcaactcagaataaatcatctgaaagatgaatgaatlaa	11400
Qy	1141	agctcagctcttaacttccagcccccaagcgctcaagtgaaatttgaatactgcatcttaagtg	12000
Db	1141	agctcagctcttaacttccagcccccaagcgctcaagtgaaatttgaatactgcatcttaagtg	12000
Qy	1201	tagagtaacacatacaactgtatgcaatggaacacagagaggaacagatataagtggtcccta	12600
Db	1201	tagagtaacacatacaactgtatgcaatggaacacagagaggaacagatataagtggtcccta	12600
Qy	1261	ccactctaatacaagaagaagaattacagagactctgattcttcaacagtatgatttgaaattc	13200
Db	1261	ccactctaatacaagaagaagaattacagagactctgattcttcaacagtatgatttgaaattc	13200
Qy	1321	aagtggtatcataatcaagggctttagattataaaactttggtgaactataactaaatagtt	13800

DB	Accession	Score	DB 1	Length	Mismatches	Indels	Gaps
Db	1321 AAGGTTATATTAAGGCTTTGATTTATAAACTTGGGACTTATACATAATATAGT	100.0%	1621	1621	0	0	0
Qy	1381 agtattctgcctcccaagttcttgatatacatcttgatataagaattcttgactata	100.0%	1621	1621	0	0	0
Db	1381 AGTATTCTGCGCTTCCAGTTGCTGTGATATATTGTTGATATTAAGATTCTGACTATA	100.0%	1621	1621	0	0	0
Qy	1441 ttctgaatgggtctcagtgaaaaaaggaaagatatactcttgaaagacatcgatatacatt	100.0%	1621	1621	0	0	0
Db	1441 TTTTGATGGGCTCTAGTGAAAAAGCAATGATATATCTTGAAGACATCGATATACATTT	100.0%	1621	1621	0	0	0
Qy	1501 attaacctcttgattctacaaatgtaagaatagagaaatgcccacaattgtatggat	100.0%	1621	1621	0	0	0
Db	1501 ATTACCTCTTGATTTCTACAAATGTAGAAATGAGAAATGCCCAAAATTGTATGTGAT	100.0%	1621	1621	0	0	0
Qy	1561 aaaagtcacgtgaaaaaataaaaaataaaaaataaaaaataaaaaataaaaaa	100.0%	1621	1621	0	0	0
Db	1561 AAAAGTCACGTGAAAAACAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA	100.0%	1621	1621	0	0	0
Qy	1621 a 1621	100.0%	1621	1621	0	0	0
Db	1621 A 1621	100.0%	1621	1621	0	0	0
RESULT 2							
ID	V61199 standard; cDNA: 1621 BP.						
AC	V61199;						
DT	06-JAN-1999 (first entry)						
DE	Full length cDNA sequence of prostate tumour clone F1-12.						
KW	Prostate; cancer; tumour; vaccine; immunogen; clone; ss.						
OS	Hom sapiens.						
PN	WO9837093-A2.						
PD	27-AUG-1998.						
PF	25-FEB-1998; U03492.						
PR	09-FEB-1998; US-020956.						
PR	25-FEB-1997; US-806099.						
PR	01-AUG-1997; US-904804.						
PA	(CORI-) CORIXA CORP.						
PI	Dillon DC, Xu J;						
DR	WPI: 98-609886/51.						
DR	P-PsDB: W71867.						
PT	Polypeptides comprising immunogenic portions of prostate proteins -						
FT	used in a vaccine for the treatment of prostate cancer						
PS	Claim 3; Page 76-77; 130pp; English.						
CC	The present sequence is a new DNA which encodes an immunogenic portion						
CC	of a prostate tumour protein. The encoded immunogen, or the DNA itself,						
CC	can be used as a vaccine for the treatment of prostate cancer. The DNA						
CC	was identified by analysis of a subtracted cDNA library obtained by						
CC	subtracting a prostate tumour cDNA expression library with a normal						
CC	tissue cDNA library.						
SQ	Sequence 1621 BP; 461 A; 330 C; 412 G; 418 T;						
Query Match							
Best Local Similarity		100.0%	Score 1621:	DB 1:	Length 1621:		
Matches 1621:		Conservative	0:	Mismatches	0:	Indels	0:
							Gaps
Qy	1 cgcctatgcatcgcagggcattcggatcatgagctgtccggctcggccggccgctt	60					
Db	1 CGCCATGGCAGCTGCGAGGCACTTCGTCATGACGTGTCGGCCCTGGCCCGCCGCTT	60					
Qy	61 ctgtacatgtctccggatgacttcggggcgcgctgtgtacgcgtggagccggccgctc	120					
Db	61 CTGTGCTATGTGCTCTGCGCTGACTTGGGGCGCGCTGTGTCACCGCGTGACCGGGCGCTC	120					
Qy	121 ccgactacacgttgagccgctctgggcccggggcaagcgctcgcctagatcgtgagacctgaagca	180					
Db	121 CCGCTACACGAGGAGCCGCTTGGGCGCGGCAAGCGCTCGCTAGTGCAGACTGAAGCA	180					
Qy	181 ggcgcgggagacgcgcgtgtcgtcgcgctctgtgcaagcgctcgcgtgtcgtcgagacc	240					
Db	181 GCCCGGGGAGACCGCGCTGCTGCGCGCTGTGCAAGCGGTGCGATGTGCTGTGGACCC	240					

This Page Blank (uspto)

QY 241 ctccgcgcggtgcatgagaaactccagctgggcccagagatctcagcggggaaa 300
DB 241 ctccgcgcgcggtgcatgagaaactccagctgggcccagagatctcagcggggaaa 300
QY 301 tccagagctattatgacagcgtgagtgatctggccagtcaggaagctccgcccgtt 360
DB 301 tccagagctattatgacagcgtgagtgatctggccagtcaggaagctccgcccgtt 360
QY 361 agctggcagagatatacaactattggcttgctcagtggtctctcacaataatggcagaag 420
DB 361 agctggcagagatatacaactattggcttgctcagtggtctctcacaataatggcagaag 420
QY 421 tggtagaactccgtaagcccgctgaaatccctggctgacttgctgctgctgctgctat 480
DB 421 tggtagaactccgtaagcccgctgaaatccctggctgacttgctgctgctgctgctat 480
QY 481 gctgcacctgggcaataatgctctcttgacccgacacgctgacagggctcaggt 540
DB 481 gctgcacctgggcaataatgctctcttgacccgacacgctgacagggctcaggt 540
QY 541 cattgatgcaaatatggtggaaggaacagcatattatgctctcttgctggaatactca 600
DB 541 cattgatgcaaatatggtggaaggaacagcatattatgctctcttgctggaatactca 600
QY 601 gaaatcgagcttggtggaagcagctcgagagacagacatgttgatggtggaagcacttc 660
DB 601 gaaatcgagcttggtggaagcagctcgagagacagacatgttgatggtggaagcacttc 660
QY 661 ctatagcactacagagacagacatggtggaatctcagctgctggaagcaataagaccca 720
DB 661 ctatagcactacagagacagacatggtggaatctcagctgctggaagcaataagaccca 720
QY 721 gttctcagagctgctgacacaaagagcttgagctaaagctgagatgagactcccaatcagat 780
DB 721 gttctcagagctgctgacacaaagagcttgagctaaagctgagatgagactcccaatcagat 780
QY 781 gagcagtgatgagcttggtggaagacagacatggtggaatctcagctgctggaagcaataagaccca 840
DB 781 gagcagtgatgagcttggtggaagacagacatggtggaatctcagctgctggaagcaataagaccca 840
QY 841 gaaagcagagctggtgcaaatcttgacggcagacagatgctggtgacccggtctcag 900
DB 841 gaaagcagagctggtgcaaatcttgacggcagacagatgctggtgacccggtctcag 900
QY 901 ttctgagaggttgctgacatgacacaaagagacaggggctggttatcaccaagtga 960
DB 901 ttctgagaggttgctgacatgacacaaagagacaggggctggttatcaccaagtga 960
QY 961 ggaagcagagacgtgagcccccccgctgacactgctggttaaacaccccgacatcccttc 1020
DB 961 ggaagcagagacgtgagcccccccgctgacactgctggttaaacaccccgacatcccttc 1020
QY 1021 ttcaaaaaggatcctttatagagaaacacactgagagatactgaaagattggatt 1080
DB 1021 ttcaaaaaggatcctttatagagaaacacactgagagatactgaaagattggatt 1080
QY 1081 cagccgagagatattatcagcttaactcagaataaataatgaaagtaagtaagtaaa 1140
DB 1081 cagccgagagatattatcagcttaactcagaataaataatgaaagtaagtaagtaaa 1140
QY 1141 agctagctcctaacctccagggcccaagctcagtgatgattgaaatgctgattacagtg 1200
DB 1141 agctagctcctaacctccagggcccaagctcagtgatgattgaaatgctgattacagtg 1200
QY 1201 taagagtaaccataaacttgatgagagaaacatgagagacagtaattacagtgctccta 1260
DB 1201 taagagtaaccataaacttgatgagagaaacatgagagacagtaattacagtgctccta 1260
QY 1261 ccaacttaacaaagaaagaaatcacagactgattctcagtgatgattgaaatgctccta 1320
DB 1261 ccaacttaacaaagaaagaaatcacagactgattctcagtgatgattgaaatgctccta 1320

QY 1321 aatggtatcatagagcttttgattataaacttggtgacttactactaataatggt 1380
DB 1321 aatggtatcatagagcttttgattataaacttggtgacttactactaataatggt 1380
QY 1381 agttattcgccttcaggttgctgataatcttgatataaagattctgacttata 1440
DB 1381 agttattcgccttcaggttgctgataatcttgatataaagattctgacttata 1440
QY 1441 tttagatggttctagtgaaaaagaaatgataatcttgaaagacatgataatctt 1500
DB 1441 tttagatggttctagtgaaaaagaaatgataatcttgaaagacatgataatctt 1500
QY 1501 atttactcttgatctcacaatgtagaaatgagagaaatgccaatgtagatgagat 1560
DB 1501 atttactcttgatctcacaatgtagaaatgagagaaatgccaatgtagatgagat 1560
QY 1561 aaaaagcagtgtagaaaaaagaaaaaagaaaaaagaaaaaagaaaaaagaaaaa 1620
DB 1561 aaaaagcagtgtagaaaaaagaaaaaagaaaaaagaaaaaagaaaaaagaaaaa 1620
QY 1621 a 1621
DB 1621 a 1621

RESULT 3
V58551
IN ***-***

This Page Blank (uspto)

[illegible]

RESULT 2

ID	V61287	standard; cDNA: 385 BP.
AC	V61287;	
DT	06-JUN-1999	(first entry)
DE	cDNA sequence of prostate tumour clone P80.	
KW	Prostate; cancer; tumour; vaccine; immunogen; clone; ss.	
OS	Homo sapiens.	
PN	M09837093-A2.	
PD	27-AUG-1998.	
PF	25-FEB-1998; U03492.	
PR	09-FEB-1998; U5-020956.	
PR	25-FEB-1997; US-806099.	
PR	01-AUG-1997; US-904804.	
PA	(COR-) CORIXA CORP.	
PI	Dillon DC, Xu J;	
DR	WPI: 98-609886/51.	
PT	Polypeptides comprising immunogenic portions of prostate proteins -	
PT	used in a vaccine for the treatment of prostate cancer	
PS	Claim 12: Page 61; 130pp: English.	
CC	The present sequence is a DNA which encodes an immunogenic portion	
CC	of a prostate tumour protein. The encoded immunogen, or the DNA itself	
CC	can be used as a vaccine for the treatment of prostate cancer. The DNA	
CC	was identified by analysis of a subtracted cDNA library obtained by	
CC	subtracting a prostate tumour cDNA expression library with a normal	
CC	tissue cDNA library.	
CC	Sequence 385 BP; 86 A; 105 C; 94 G; 100 T;	

Query Match	100.0%	Score 385;	DB 1;	Length 385;
Best Local Similarity	100.0%	Pred. No. 3	5e-119;	
Matches 385;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	actacacacactccactctgcccctgttgagacacttctgcccagcacttagaattctga	60	
Db	1	ACTACACACTCTCACTTCCCTTGTGAGACACTTTGTCACGACTTTAGGAATGCTGA	60	
QY	61	gtctcgagccaagccaactctcatgtgtcaagattgcccgagcagacatctcaagtcttc	120	
Db	61	GGTCGGACCAAGCCACTTCATGTCCAAGATTGCCACACACACTCAGTCAAGATTCC	120	
QY	121	ccctctcaaaaaagggagacttgctctcaaaaaaagaagctcagccagatctgttagagcagc	180	
Db	121	CCCTTTAAAAAAGGGAGCTTGCTTTAAAAAAGAAGTCTAGCCACAGATTGTTAGAGACAG	180	
QY	181	tgtgtctgtctgtgagaattcaactctttgagaagctctccctctgagaactgacttttagag	240	
Db	181	TGTGTCTGTCTGTGAGATTCACTTTTGAAGAAGATTCTCCTTGAAACTGTACTTTTAGAG	240	
QY	241	ctggagagctctgtgacatgagatggagggctgtgtcatctcagacactccttagctctgtg	300	
Db	241	CTGGGAGAGCTTGGCACAATGAGATGGGGCTGGTCTGATCTCAGCACTCTTAGTCTGCTTG	300	
QY	301	ccctctcccaagggcccccagcctgtgccaacactgtcttacaagggcactctcaatgtcccat	360	
Db	301	CCCTCTCCCAAGGGCCCCAGGCGCTGGCCACACACTGTTCACAGGGCACTTCATGATGCCCATAC	360	
QY	361	catagattctctgtctagtgagacct	385	
Db	361	CATAGTTCTCTGTCTAGTGAAGCCGT	385	

This Page Blank (uspto)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
84

QY 301 cctctcccaaggcccaagctgagccacacactgtctacagggcactctcagatgcccacatc 360
DB 301 CCTCTCCAGGGCCCGACGCTGGCCACACCTGCTTACAGGGACGCTCAGATGCCCATAC 360
QY 361 catagttctgtgtcagtagtgacct 385
DB 361 CATAGTTCTGTGTAGTAGGACCGT 385

RESULT 2

V61287
ID V61287 standard; cDNA; 385 BP.
AC V61287;
DE 06-JAN-1999 (first entry)
CD cDNA sequence of prostate tumour clone P80.
KM Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN MO9837093-A2.
PD 27-AUG-1998.
PR 25-FEB-1998; U03492.
PR 09-FEB-1998; US-020956.
PR 25-FEB-1997; US-806099.
PR 01-AUG-1997; US-904804.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI; 98-609886/51.
PT Polypeptides comprising immunogenic portions of prostate proteins -
PI used in a vaccine for the treatment of prostate cancer
PS Claim 12; Page 61; 130pp; English.
CC The present sequence is a DNA which encodes an immunogenic portion
CC of a prostate tumour protein. The encoded immunogen, or the DNA itself,
CC can be used as a vaccine for the treatment of prostate cancer. The DNA
CC was identified by analysis of a subtracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
CC tissue cDNA library.
SQ Sequence 385 BP; 86 A; 105 C; 94 G; 100 T;

Query Match 100.0%; Score 385; DB 1; Length 385;

Best Local Similarity 100.0%; Pred. No. 3.5e-119; Mismatches 0; Indels 0; Gaps 0;

QY 1 actaacacactccactgacctgtgagacacattgtccacgacctttagaagtctga 60
DB 1 ACTACACACACTCCACTGCTGCTTGAGAGACACTTGTCCAGCACTTAGGAATGCTGA 60
QY 61 gctggaccagcagcatctcatgtgcaaatgtgcccagcagacatcaggtctcgaggttc 120
DB 61 GCTGGACCGACCATCTCATGTGCAAGATTGCCAGCAGACATCAGGTCTGAGAGTTC 120
QY 121 ccccttctaaaaaaggagactgtctctaaaaaaggagctcagccagactgtgtagaagcagc 180
DB 121 CCTTTTAAAAAAGGGGACTTGTCTTAAAAAAGAGCTAGCCAGCATCTGTAGACACAC 180
QY 181 tgtgtctgtcgtggaagatctcacttttagagagagttctcctctgagacctgacctttagagg 240
DB 181 TGTGCTGTCTGTGAGATTCATCTTTGAGAGAGTTCCTCTGAGACCTGATCTTAGAGG 240
QY 241 ctgggagagcttgcacatagatagggctggtgtgtctcctcagacctccttagtctcttg 300
DB 241 CTGGGAGAGCTTGCACATAGATAGAGGGGCTGCTGTGATCTCAGACATCTTAGTCTCTGG 300
QY 301 cctctcccaaggcccaagctgagccacacactgtctacagggcactctcagatgcccacatc 360
DB 301 CCTCTCCAGGGCCCGACGCTGGCCACACCTGCTTACAGGGACGCTCAGATGCCCATAC 360
QY 361 catagttctgtgtcagtagtgacct 385
DB 361 CATAGTTCTGTGTAGTAGGACCGT 385

RESULT 3

V58544/c

ID V58544 standard; cDNA; 385 BP.

AC V58544;

DE 08-DEC-1998 (first entry)

CD Prostate tumour specific gene clone P80.

KM Prostate tumour specific gene; human; prostate cancer; detection;

OS therapy; ss.

PN MO9837418-A2.

PD 27-AUG-1998.

PR 25-FEB-1998; U03690.

PR 09-FEB-1998; US-904809.

PR 25-FEB-1997; US-806596.

PR 01-AUG-1997; US-904809.

PA (CORI-) CORIXA CORP.

PI Dillon DC, Xu J;

DR WPI; 98-480805/41.

PT Novel human prostate specific tumour protein and fragments - useful

PI for detecting and treating prostate cancers

PS Claim 1; Page 64; 141pp; English.

CC This sequence represents a human prostate tumour specific gene, and can

CC be used in the method of the invention. The method is for detecting

CC prostate cancer comprises contacting a biological sample with an agent

CC able to bind an immunogenic portion of a prostate protein (such as

CC encoded by this sequence). An antibody which binds to an immunogenic

CC portion of the prostate protein, and the method can be used to detect,

CC monitor progression of, or treat prostate cancers. The antibody may

CC also be conjugated to a therapeutic agent for use in therapy of prostate

CC cancers.
SQ Sequence 385 BP; 86 A; 105 C; 94 G; 100 T;

Query Match 21.8%; Score 84; DB 1; Length 385;

Best Local Similarity 64.5%; Pred. No. 1e-18; Mismatches 160; Conservative 0; Mismatches 80; Indels 8; Gaps 2;

QY 48 ttagaatgctgaggtcgagaccagccacatctcatgtgcaagatgcccagc---agac 103
DB 48 TTAGAGAGTCTGATGATCAGACACGCCCATCTCATGTGCAAGACTGCTCTTAAG 232
QY 104 atcaggtctgagaggtccctcttctaaaaaaggagagctgctctaaaaaaggagctcagca 163
DB 104 ATCAGGCTCAGAGAGACACTCTCTCAAAAGGAAATCTCCAGCAGACAGCTGCTCTTA 172
QY 164 cgatgtctgagagcagctgtgtgtgtgtgagagatctcacttttagagagaggtctcctctga 223
DB 164 CAGATCGTGCCTAGACTCTCTTTTAAAGCAAGTCCCTTTTAAAGGGAACTCTCA 112
QY 224 gacctgacctttagagagctgagcagctctgacacatgagatgagggctgtgtctgacctcagc 283
DB 224 GACCTGATGTCT---GCTGGCAGATCTTGACATGAGATGTGCTGCTCGACCTCAGC 56
QY 284 acctctta 291
DB 284 ATTCCTAA 48

RESULT 4

V61287/c

ID V61287 standard; cDNA; 385 BP.
AC V61287;
DE 06-JAN-1999 (first entry)
CD cDNA sequence of prostate tumour clone P80.
KM Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
OS Homo sapiens.
PN MO9837093-A2.
PD 27-AUG-1998.
PR 25-FEB-1998; U03492.
PR 09-FEB-1998; US-020956.
PR 25-FEB-1997; US-806099.
PR 01-AUG-1997; US-904804.
PA (CORI-) CORIXA CORP.
PI Dillon DC, Xu J;
DR WPI; 98-609886/51.

CC be used to develop products for diagnosis and therapy. The proteins
CC obtained may have cytokine activity, cell proliferation/differentiat
CC activity, haematopoiesis regulating activity, tissue growth regulati
CC activity, reproductive hormone regulating activity, chemotactic/
CC chemokinetic activity, haemostatic and thrombotic activity, repress

Query Match	9.4%	Score 36.2;	DB 1;	Length 429;
Best Local Similarity	72.3%	Pred No. 0.0099		
SQ Sequence 429 BP;	78 A;	132 C;	109 G;	108 T;

[illegible]

```

Db 100 AGAGTGCTCAGGTCACACCATCCCACTTATCGGCAAGAACGCCCTGACATGATCAGG 41
Oy 110 tctga 114
    |||||
Db 40 TCTGA 36

RESULT 7
078233/c
ID 078233: standard; DNA: 1336 BP.
AC 078233:
DR 10-UTL-1995 (first entry)
DE Alkaline serine protease gene from Paecilomyces lilacinus.
KW Serine protease; nematode; egg; parasite; fungus; wheat; cabbage;
KW proase; primer; amplify; PCR; alkaline protease; parasitic nematode;
KW subtilisin-like protease; plant; plant cell; cyst; root-knot; lesion;
KW Heterodermidae; potato; sugar beet; cyst nematode; ds.
OS Paecilomyces lilacinus.
PN EP-623672-A.
09-NOV-1994.
04-MAY-1993: 107233.
04-MAY-1993: EP-107233.
PA (REPL.) RES INST PLANT PROTECTION.
PI Bonants PJM, Den Bellder E, Filters PFL, Waalwijk C.
DR WPI: 94-343307/43.
PT Use of protease from Paecilomyces lilacinus - to control plant
PS parasitic nematodes esp. root-knot nematodes of potato plants
PS Claim 7: Page 15-16; 35pp; English.
CC The nucleotide sequence of the novel alkaline serine protease isolated
CC from the nematode egg-parasitic fungus Paecilomyces lilacinus. The gene
CC encodes a protease of 33.5 kD which has an isoelectric point of pI10.
CC The protease has optimal activity at pH10.3 and 60 deg. C. The gene was
CC amplified from P. lilacinus genomic DNA using the primers (078234-5) based
CC on homologous amino acid sequence between the novel protease and a.a.
CC sequences which are conserved among subtilisin-like proteases. The
CC sequences include regions at the N-terminus of the protein (R65936) and
CC around the active site histidine residue (R65937). The resulting 240 bp
CC fragment was used to screen a P. lilacinus cDNA library in lambda ZAP to
CC obtain the full length gene encoding the protease. The protease is used
CC to control plant parasitic nematodes by controlling the action of the
CC nematodes on plants and plant cells. The gene encoding the protease can
CC be used to control plant parasitic cyst, root-knot or lesion nematodes
CC especially root-knot nematodes e.g. those in the Heterodermidae family
CC which include the potato and sugar beet cyst nematodes.
SQ Sequence 1336 BP; 307 A; 446 C; 318 G; 265 T;

Query Match 9.4%; Score 36.2; DB 1: Length 1336;
Best Local Similarity 49.7%; Pred. No. 0.016;
Matches 92; Conservative 0; Mismatches 93; Indels 0; Gaps 0;

```

```

DE Streptococcus pneumoniae genome fragment SEQ ID NO:173.
KW Streptococcus pneumoniae; S. pneumoniae; genome; diagnosis; assay;
KW computer readable medium; vaccine; pharmaceutical composition; ds.
OS Streptococcus pneumoniae.
PN M09818931-A2.
PD 07-MAR-1998.
PF 30-OCT-1997; 019588.
PR 31-OCT-1996; US-029960.
PA (HUMA-) HUMAN GENOME SCI INC.
PI Barash SC, Choi GH, Dillon PJ, Dougherty BA, Fannon M,
PI Kunsch CA, Rosen CA.
DR WPI: 96-272225/24.
PT Computer-readable medium with recorded Streptococcus pneumoniae
PT polynucleotide sequences - useful in diagnostic kits and assays, and
PT pharmaceutical compositions and vaccines for Streptococcus
PT pneumoniae.
PS Claim 1: Page 1101-1103; 1409pp; English.
CC The present invention describes a computer readable medium which has
CC the nucleotide sequences SEQ ID NO:1 to 391 (V52134 to V52524) recorded
CC on it, or a representative fragment or a sequence at least 95% identical
CC to SEQ ID NO:1 to 391. The nucleotide sequences depicted in SEQ ID NO:1
CC to 391 (V52134 to V52524) are genomic fragments from Streptococcus
CC pneumoniae. The present invention also describes an isolated nucleic acid
CC molecule encoding a homologue of any of the fragments of the S. pneumoniae
CC genome (SEQ ID NO:1 to 391) where the nucleic acid molecule is produced
CC by a process comprising: (a) screening a genomic DNA library using as a
CC probe a target sequence defined by any of the sequences in SEQ ID NO:1
CC to 391, identifying members of the library which contain sequences
CC that hybridise to the target sequence and isolating the nucleic acid
CC molecules from the members; or (b) isolating mRNA, DNA or cDNA produced
CC from an organism, amplifying nucleic acid molecules whose nucleotide
CC sequence is homologous to amplification primers derived from the
CC fragment of the S. pneumoniae genome to prime the amplification and
CC isolating the amplified sequences. The computer readable medium can be
CC used in a computer-based system for identifying fragments of the
CC S. pneumoniae genome of commercial importance, or expression modulating
CC fragments of the S. pneumoniae genome. Products from the present
CC invention can be used in diagnosis kits and assays, and pharmaceutical
CC compositions and vaccines for S. pneumoniae.
SQ Sequence 4185 BP; 1257 A; 992 C; 749 G; 1187 T;

Query Match 8.7%; Score 33.4; DB 1: Length 4185;
Best Local Similarity 52.5%; Pred. No. 0.23;
Matches 73; Conservative 0; Mismatches 66; Indels 0; Gaps 0;

```

```

RESULT 8
ID V52306 standard; DNA: 4185 BP.
AC V52306:
DR 23-OCT-1998 (first entry)

```

```

RESULT 9
ID V23127 standard; cDNA: 5053 BP.
AC V23127:
DR 14-AUG-1998 (first entry)
DE cDNA of protein with Rho protein-binding and kinase activity.
KW Rho protein-binding activity; protein kinase activity; inhibitor;
KW smooth muscle fibre formation; smooth muscle contraction;
KW circulatory disease; treatment; tumour formation; metastasis inhibitor;
KW autoimmune disease; platelet aggregation inhibitor; ss.
OS Bos sp.
FH Key Location/Qualifiers
FT 1..4167
FT CDS /tag= a

```

FT misc.feature 3889. .3936
FT /*tag- b
FT /note= "the amino acid residues encoded by these
FT nucleotides do not appear in the protein
FT sequence"
PN J1013187-A.
PD 06-MAY-1998.
PF 20-NOV-1996: 324594.
PR 23-AUG-1996: JP-241061.
PR 20-NOV-1995: JP-325129.
PR 05-JAN-1996: JP-017150.
PR 26-APR-1996: JP-131206.
PA (KIRI) KIRIN BREWERY KK.
DR WPI: 98-315475/28.
DR P-PSDB: W56473.
PT Bovine and human Rho protein-binding protein kinase - used to
PT develop products for treatment of smooth muscle disorders,
PT circulatory disease, cancer and autoimmune disease
PT Disclosure: Pages 39-44; 66pp; Japanese.
CC The present sequence encodes a protein that has Rho protein-binding
CC activity and protein kinase activity. Inhibitors of the Rho-binding
CC protein kinase can be used to inhibit smooth muscle fibre formation
CC and smooth muscle contraction. Other applications of the Rho
CC protein-binding agent and its products are as a circulatory disease
CC treating agent, a tumour formation or metastasis inhibitor, an
CC autoimmune disease treating agent or a platelet aggregation inhibitor.
SQ Sequence 5053 BP; 1816 A; 879 C; 1092 G; 1266 T;

Query Match 8.6%; Score 33; DB 1; Length 5053;
Best Local Similarity 54.5%; Pred. No. 0.35;
Matches 66; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY 196 attcaactttagagagcttccctcctcagaccctgactttagagagctggagcttgc 255
DB 4464 ATGCATCTAGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATG 4405
QY 256 catgagatggggcgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 315
DB 4404 CATGATATTTCTTATTTATTAACCAATCACTGTGTGTTCACTGTGTGTCCAAAGGAGC 4345
QY 316 c 316
DB 4344 C 4344

ID 10
AC N70956 standard; cDNA; 1970 BP.
DT 15-APR-1991 (first entry)
DE Sequence of human skin collagenase cDNA
KW Enzyme: protease; ss.
OS Homo sapiens.
FS Key
FT cds
FT Location/Qualifiers
FT 69.1478
FT poly-a-signal 1942. .1947
FT /*tag- a
FT /*tag- b
PN GB2182665-A.
PD 20-MAY-1987.
PF 11-NOV-1986: 026914.
PR 12-NOV-1985: US-797262.
PA (MONS) MONSANTO CO.
PA (UNIM) UNIV OF WASHINGTON.
PI Eisen AZ, Goldberg GI, Bauer EA;
DR WPI: 87-137944/20.
DR P-PSDB: P70611.
PT New human skin fibroblast collagenase - is obtd. by recombinant
PT dna procedures for treating hypertrophic scars, keloids and
PT intervertebral disc disease
PS Claim 2; Fig 2; 10pp; English.
CC Cytoplasmic RNA was prepd. by using normal adult human skin

CC fibroblasts to give conditioned medium, and procollagenase was
CC purified. Protein sequencing, primer extension reaction and
CC construction of a cDNA library were carried out. Human skin
CC fibroblast protein is pref. glycosylated at Asn 120 and Asn 143.
SQ Sequence 1970 BP; 588 A; 409 C; 443 G; 530 T;

Query Match 7.9%; Score 30.6; DB 1; Length 1970;
Best Local Similarity 58.1%; Pred. No. 1.4;
Matches 54; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

QY 21 ccttgagacacttctccagacactttagaagctgagctggaccacacatctc 80
DB 351 CCTGATGGCTCAGTTGTTGCTCCTCAGTGAAGAACCTCCTGGAGCAACACATCTG 410
QY 81 atgtcgaagattgccagacacatcaggtctg 113
DB 411 AGTACAGAGATTGAAATTACAGCCAGATTGTG 443

RESULT 11
ID Q20602/c
AC Q20602; standard; cDNA; 8937 BP.
DT 06-MAY-1992 (first entry)
DE Nf1 gene.
KW von Recklinghausen neurofibromatosis disease; autosomal dominant; ss;
KW gene therapy.
OS Homo sapiens.
FS Key
FT cds
FT Location/Qualifiers
FT 190.8646
FT /*tag- a
PN W09200387-A.
PD 09-JAN-1992.
PF 28-JUN-1991: U04624.
PR 29-JUN-1990: US-547090.
PA (UNMI) UNIV OF MICHIGAN.
PI Collins FS, Wallace MR, Marchuk DA, Andersen LB, Gutmann DH;
DR WPI: 92-041568/05.
DR P-PSDB: R22268.
PT DNA sequences to von-Recklinghausen neurofibromatosis gene - and
PT derived amino acid sequences and probes for screening Nf1 in early
PT stages of disease
PS Claim 22; Page 39; 122pp; English.
CC This is the cDNA sequence of the von Recklinghausen neurofibromatosis
CC (Nf1) gene. The gene, its product, probes and antibodies to its
CC product can be used in hybridisation and immunological assays to
CC screen for the presence of a normal or defective Nf1 gene or gene
CC product. Functional assays to measure levels of gene function can
CC also be used for diagnosis or to monitor treatment. Patient therapy
CC through supplementation with the normal Nf1 product which can be
CC produced by recombinant techniques is also possible. In addition the
CC disease may be cured or controlled through gene therapy. See also
CC Q20603 and Q20604.
SQ Sequence 8937 BP; 2595 A; 2015 C; 1880 G; 2447 T;

Query Match 7.8%; Score 30; DB 1; Length 8937;
Best Local Similarity 50.0%; Pred. No. 4.5;
Matches 75; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 166 atgtgtagagcagctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 225
DB 324, ATGATTAGACATTCCTGTGTGTCTCAGTACTACTTGTGTGTGTGTGTGTGTGTGT 265
QY 226 cctgactttagagcgtggcagcgtcttgcacatgagatgggtgtgtctatctcagcac 285
DB 264 TGTTTTATTGTGAGCTGCTGCTGGAAGCGGCTGACACGCGCTGAGCAATTCACCGG 205
QY 286 tccttagtctgtctgtctccagggccc 315
DB 204 CCTGTGGCGGCGCATGTCTCTCCGCGGCC 175

